US20070025927A1 - Odorless formulation for treating mucosal discontinuities - Google Patents
Odorless formulation for treating mucosal discontinuities Download PDFInfo
- Publication number
- US20070025927A1 US20070025927A1 US11/533,194 US53319406A US2007025927A1 US 20070025927 A1 US20070025927 A1 US 20070025927A1 US 53319406 A US53319406 A US 53319406A US 2007025927 A1 US2007025927 A1 US 2007025927A1
- Authority
- US
- United States
- Prior art keywords
- acid
- formulation
- sulfuric acid
- bottle
- exfoliating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 238000009472 formulation Methods 0.000 title abstract description 66
- 230000009965 odorless effect Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 42
- WHOZNOZYMBRCBL-OUKQBFOZSA-N (2E)-2-Tetradecenal Chemical compound CCCCCCCCCCC\C=C\C=O WHOZNOZYMBRCBL-OUKQBFOZSA-N 0.000 claims description 32
- 229940044654 phenolsulfonic acid Drugs 0.000 claims description 32
- QDRCGSIKAHSALR-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzene-1-sulfonic acid Chemical compound COC1=CC(S(O)(=O)=O)=CC=C1O QDRCGSIKAHSALR-UHFFFAOYSA-N 0.000 claims description 26
- 229940057818 guaiacolsulfonic acid Drugs 0.000 claims description 26
- 230000007246 mechanism Effects 0.000 claims description 13
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims 6
- 239000006071 cream Substances 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract description 135
- 150000008054 sulfonate salts Chemical class 0.000 abstract description 8
- 150000003460 sulfonic acids Chemical class 0.000 abstract description 7
- 150000002989 phenols Chemical class 0.000 abstract description 5
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 51
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 229960003742 phenol Drugs 0.000 description 28
- 229960001867 guaiacol Drugs 0.000 description 25
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 22
- 208000002399 aphthous stomatitis Diseases 0.000 description 20
- 239000005297 pyrex Substances 0.000 description 20
- 208000025865 Ulcer Diseases 0.000 description 19
- 239000002253 acid Substances 0.000 description 19
- 231100000397 ulcer Toxicity 0.000 description 16
- 230000003902 lesion Effects 0.000 description 15
- UAHUSJDFWAEKNV-UHFFFAOYSA-N azanium;2-hydroxybenzenesulfonate Chemical compound [NH4+].OC1=CC=CC=C1S([O-])(=O)=O UAHUSJDFWAEKNV-UHFFFAOYSA-N 0.000 description 10
- 210000000214 mouth Anatomy 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- -1 alkaline earth metal salts Chemical class 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 229960003666 liquefied phenol Drugs 0.000 description 9
- 230000003134 recirculating effect Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000035876 healing Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000007565 gingivitis Diseases 0.000 description 5
- 239000003589 local anesthetic agent Substances 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- WHRZCXAVMTUTDD-UHFFFAOYSA-N 1h-furo[2,3-d]pyrimidin-2-one Chemical compound N1C(=O)N=C2OC=CC2=C1 WHRZCXAVMTUTDD-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 235000006173 Larrea tridentata Nutrition 0.000 description 4
- 244000073231 Larrea tridentata Species 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 229960002126 creosote Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- QFRKWSPTCBGLSU-UHFFFAOYSA-M potassium 4-hydroxy-3-methoxybenzene-1-sulfonate Chemical compound [K+].COC1=CC(S([O-])(=O)=O)=CC=C1O QFRKWSPTCBGLSU-UHFFFAOYSA-M 0.000 description 4
- 229940069505 potassium guaiacolsulfonate Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010014982 Epidermal and dermal conditions Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000001277 chronic periodontitis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229930003633 citronellal Natural products 0.000 description 3
- 235000000983 citronellal Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 201000001245 periodontitis Diseases 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229940071643 prefilled syringe Drugs 0.000 description 3
- 238000007614 solvation Methods 0.000 description 3
- 229940032330 sulfuric acid Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- NWGGKKGAFZIVBJ-UHFFFAOYSA-N antrafenine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCOC(=O)C=3C(=CC=CC=3)NC=3C4=CC=C(C=C4N=CC=3)C(F)(F)F)CC2)=C1 NWGGKKGAFZIVBJ-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 208000019884 chronic gingivitis Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229950009121 naepaine Drugs 0.000 description 2
- UYXHCVFXDBNRQW-UHFFFAOYSA-N naepaine Chemical compound CCCCCNCCOC(=O)C1=CC=C(N)C=C1 UYXHCVFXDBNRQW-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229940044652 phenolsulfonate Drugs 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HGKAMARNFGKMLC-MOPGFXCFSA-N (2r)-2-[(4r)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine Chemical compound C([C@@H]1[C@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-MOPGFXCFSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- CAFOIGUDKPQBIO-BYIOMEFUSA-N (r)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-[6-(3-methylbutoxy)quinolin-4-yl]methanol Chemical compound C1=C(OCCC(C)C)C=C2C([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 CAFOIGUDKPQBIO-BYIOMEFUSA-N 0.000 description 1
- ZZMSHBOVYPIYOB-UHFFFAOYSA-N 1,4-diphenylpyrazolidine-3,5-dione Chemical compound O=C1NN(C=2C=CC=CC=2)C(=O)C1C1=CC=CC=C1 ZZMSHBOVYPIYOB-UHFFFAOYSA-N 0.000 description 1
- XOZLRRYPUKAKMU-UHFFFAOYSA-N 1,5-dimethyl-2-phenyl-4-(propan-2-ylamino)-3-pyrazolone Chemical compound O=C1C(NC(C)C)=C(C)N(C)N1C1=CC=CC=C1 XOZLRRYPUKAKMU-UHFFFAOYSA-N 0.000 description 1
- WQAQKERCWPUIMH-UHFFFAOYSA-N 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CN1C(C)=CC(=O)N1C1=CC=CC=C1 WQAQKERCWPUIMH-UHFFFAOYSA-N 0.000 description 1
- FMBVHKPWDJQLNO-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC(F)=C1 FMBVHKPWDJQLNO-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- NYIZXMGNIUSNKL-UHFFFAOYSA-N 2,3-diacetyloxybenzoic acid Chemical group CC(=O)OC1=CC=CC(C(O)=O)=C1OC(C)=O NYIZXMGNIUSNKL-UHFFFAOYSA-N 0.000 description 1
- ZLMQPGUWYWFPEG-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-butoxybenzoate Chemical compound CCCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC ZLMQPGUWYWFPEG-UHFFFAOYSA-N 0.000 description 1
- QNIUOGIMJWORNZ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-butoxybenzoate Chemical compound CCCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 QNIUOGIMJWORNZ-UHFFFAOYSA-N 0.000 description 1
- DDSFKIFGAPZBSR-UHFFFAOYSA-N 2-[(2-acetyloxyphenyl)-oxomethoxy]benzoic acid Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1C(O)=O DDSFKIFGAPZBSR-UHFFFAOYSA-N 0.000 description 1
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 description 1
- BOFYHBVFGWJLIZ-UHFFFAOYSA-N 2-[2-(diethylamino)ethoxy]-n-phenylbenzamide Chemical compound CCN(CC)CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1 BOFYHBVFGWJLIZ-UHFFFAOYSA-N 0.000 description 1
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 1
- BURBNIPKSRJAIQ-UHFFFAOYSA-N 2-azaniumyl-3-[3-(trifluoromethyl)phenyl]propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(C(F)(F)F)=C1 BURBNIPKSRJAIQ-UHFFFAOYSA-N 0.000 description 1
- XCHHJFVNQPPLJK-UHFFFAOYSA-N 2-carboxyphenolate;1h-imidazol-1-ium Chemical compound C1=CNC=N1.OC(=O)C1=CC=CC=C1O XCHHJFVNQPPLJK-UHFFFAOYSA-N 0.000 description 1
- MECVOSKQBMPUFG-UHFFFAOYSA-N 2-carboxyphenolate;morpholin-4-ium Chemical compound C1COCCN1.OC(=O)C1=CC=CC=C1O MECVOSKQBMPUFG-UHFFFAOYSA-N 0.000 description 1
- MMAFPMQOIUHLNH-UHFFFAOYSA-N 2-hydroxy-3-methoxybenzenesulfonic acid Chemical class COC1=CC=CC(S(O)(=O)=O)=C1O MMAFPMQOIUHLNH-UHFFFAOYSA-N 0.000 description 1
- UJABSZITRMATFL-UHFFFAOYSA-N 2-methyl-5-phenylfuran-3-carbonyl chloride Chemical compound ClC(=O)C1=C(C)OC(C=2C=CC=CC=2)=C1 UJABSZITRMATFL-UHFFFAOYSA-N 0.000 description 1
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 description 1
- YTRMTPPVNRALON-UHFFFAOYSA-N 2-phenyl-4-quinolinecarboxylic acid Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=CC=C1 YTRMTPPVNRALON-UHFFFAOYSA-N 0.000 description 1
- FFKUDWZICMJVPA-UHFFFAOYSA-N 2-phosphonooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OP(O)(O)=O FFKUDWZICMJVPA-UHFFFAOYSA-N 0.000 description 1
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 1
- LBFGQUCAQWAFNN-UHFFFAOYSA-N 4-ethyl-2-(1-methylpiperidin-4-yl)-5-phenyl-1h-pyrazol-3-one Chemical compound O=C1C(CC)=C(C=2C=CC=CC=2)NN1C1CCN(C)CC1 LBFGQUCAQWAFNN-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- PCYLDXMXEPSXFW-UHFFFAOYSA-N 6-amino-2-(2-chloroethyl)-2,3-dihydro-1,3-benzoxazin-4-one Chemical compound O1C(CCCl)NC(=O)C2=CC(N)=CC=C21 PCYLDXMXEPSXFW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- LIAWQASKBFCRNR-UHFFFAOYSA-N Bucetin Chemical compound CCOC1=CC=C(NC(=O)CC(C)O)C=C1 LIAWQASKBFCRNR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- DJEIHHYCDCTAAH-UHFFFAOYSA-N Mofezolac (TN) Chemical compound C1=CC(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1 DJEIHHYCDCTAAH-UHFFFAOYSA-N 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 1
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- BRZANEXCSZCZCI-UHFFFAOYSA-N Nifenazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C)C(C)=C1NC(=O)C1=CC=CN=C1 BRZANEXCSZCZCI-UHFFFAOYSA-N 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 206010044546 Traumatic ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- VPRGXNLHFBBDFS-UHFFFAOYSA-N [3-(diethylamino)-1-phenylpropyl] benzoate Chemical compound C=1C=CC=CC=1C(CCN(CC)CC)OC(=O)C1=CC=CC=C1 VPRGXNLHFBBDFS-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- TWIIVLKQFJBFPW-UHFFFAOYSA-N acetaminosalol Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1O TWIIVLKQFJBFPW-UHFFFAOYSA-N 0.000 description 1
- 229950007008 acetaminosalol Drugs 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- OGWGWBWZZQJMNO-UHFFFAOYSA-N acetic acid;5-bromo-2-hydroxybenzoic acid Chemical compound CC(O)=O.OC(=O)C1=CC(Br)=CC=C1O OGWGWBWZZQJMNO-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- 229960004685 aloxiprin Drugs 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229950008211 ambucaine Drugs 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- UQNCVOXEVRELFR-UHFFFAOYSA-N aminopropylone Chemical compound O=C1C(NC(=O)C(N(C)C)C)=C(C)N(C)N1C1=CC=CC=C1 UQNCVOXEVRELFR-UHFFFAOYSA-N 0.000 description 1
- 229950002372 aminopropylone Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940063284 ammonium salicylate Drugs 0.000 description 1
- HPITVGRITATAFY-UHFFFAOYSA-N amolanone Chemical compound O=C1OC2=CC=CC=C2C1(CCN(CC)CC)C1=CC=CC=C1 HPITVGRITATAFY-UHFFFAOYSA-N 0.000 description 1
- 229950009452 amolanone Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 229950004064 antrafenine Drugs 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 1
- KMGARVOVYXNAOF-UHFFFAOYSA-N benzpiperylone Chemical compound C1CN(C)CCC1N1C(=O)C(CC=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 KMGARVOVYXNAOF-UHFFFAOYSA-N 0.000 description 1
- 229950007647 benzpiperylone Drugs 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- REHLODZXMGOGQP-UHFFFAOYSA-N bermoprofen Chemical compound C1C(=O)C2=CC(C(C(O)=O)C)=CC=C2OC2=CC=C(C)C=C21 REHLODZXMGOGQP-UHFFFAOYSA-N 0.000 description 1
- 229950007517 bermoprofen Drugs 0.000 description 1
- 229950005028 betoxycaine Drugs 0.000 description 1
- CXYOBRKOFHQONJ-UHFFFAOYSA-N betoxycaine Chemical compound CCCCOC1=CC=C(C(=O)OCCOCCN(CC)CC)C=C1N CXYOBRKOFHQONJ-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- 229960005470 bucetin Drugs 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960003354 bumadizone Drugs 0.000 description 1
- FLWFHHFTIRLFPV-UHFFFAOYSA-N bumadizone Chemical compound C=1C=CC=CC=1N(C(=O)C(C(O)=O)CCCC)NC1=CC=CC=C1 FLWFHHFTIRLFPV-UHFFFAOYSA-N 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960003369 butacaine Drugs 0.000 description 1
- QTNZYVAMNRDUAD-UHFFFAOYSA-N butacetin Chemical compound CC(=O)NC1=CC=C(OC(C)(C)C)C=C1 QTNZYVAMNRDUAD-UHFFFAOYSA-N 0.000 description 1
- 229950011189 butacetin Drugs 0.000 description 1
- 229960000400 butamben Drugs 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- 229960001290 butanilicaine Drugs 0.000 description 1
- VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 description 1
- 229950009376 butethamine Drugs 0.000 description 1
- WDICTQVBXKADBP-UHFFFAOYSA-N butethamine Chemical compound CC(C)CNCCOC(=O)C1=CC=C(N)C=C1 WDICTQVBXKADBP-UHFFFAOYSA-N 0.000 description 1
- 229960002463 butoxycaine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- NQIZDFMZAXUZCZ-UHFFFAOYSA-N carbifene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC)C(=O)N(C)CCN(C)CCC1=CC=CC=C1 NQIZDFMZAXUZCZ-UHFFFAOYSA-N 0.000 description 1
- 229950003365 carbifene Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- OAYRYNVEFFWSHK-UHFFFAOYSA-N carsalam Chemical compound C1=CC=C2OC(=O)NC(=O)C2=C1 OAYRYNVEFFWSHK-UHFFFAOYSA-N 0.000 description 1
- 229950004289 carsalam Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- YEKMWXFHPZBZLR-UHFFFAOYSA-N chlorthenoxazine Chemical compound C1=CC=C2OC(CCCl)NC(=O)C2=C1 YEKMWXFHPZBZLR-UHFFFAOYSA-N 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960002468 cinchophen Drugs 0.000 description 1
- UVTLONZTPXCUPU-ZNMIVQPWSA-N ciramadol Chemical compound C([C@@H]1[C@@H](N(C)C)C=2C=C(O)C=CC=2)CCC[C@H]1O UVTLONZTPXCUPU-ZNMIVQPWSA-N 0.000 description 1
- 229950007653 ciramadol Drugs 0.000 description 1
- DGMZLCLHHVYDIS-UHFFFAOYSA-N clometacin Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 1
- 229950001647 clometacin Drugs 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001209 clonixin Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- CYZWCBZIBJLKCV-RMKNXTFCSA-N cropropamide Chemical compound CN(C)C(=O)C(CC)N(CCC)C(=O)\C=C\C CYZWCBZIBJLKCV-RMKNXTFCSA-N 0.000 description 1
- 229950008982 cropropamide Drugs 0.000 description 1
- LSAMUAYPDHUBQD-RMKNXTFCSA-N crotetamide Chemical compound CN(C)C(=O)C(CC)N(CC)C(=O)\C=C\C LSAMUAYPDHUBQD-RMKNXTFCSA-N 0.000 description 1
- 229950008678 crotetamide Drugs 0.000 description 1
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 1
- 229960004741 cyclomethycaine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 229950004665 dexoxadrol Drugs 0.000 description 1
- HGKAMARNFGKMLC-RBUKOAKNSA-N dexoxadrol Chemical compound C([C@H]1[C@@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-RBUKOAKNSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- PCXMKBOWWVXEDT-UHFFFAOYSA-N difenamizole Chemical compound CN(C)C(C)C(=O)NC1=CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PCXMKBOWWVXEDT-UHFFFAOYSA-N 0.000 description 1
- 229950000061 difenamizole Drugs 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 229950010160 dimethocaine Drugs 0.000 description 1
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 1
- 229960002228 diperodon Drugs 0.000 description 1
- 229960000842 dipyrocetyl Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- 229950010996 enfenamic acid Drugs 0.000 description 1
- HLNLBEFKHHCAMV-UHFFFAOYSA-N enfenamic acid Chemical compound OC(=O)C1=CC=CC=C1NCCC1=CC=CC=C1 HLNLBEFKHHCAMV-UHFFFAOYSA-N 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PXBFSRVXEKCBFP-UHFFFAOYSA-N etersalate Chemical compound C1=CC(NC(=O)C)=CC=C1OCCOC(=O)C1=CC=CC=C1OC(C)=O PXBFSRVXEKCBFP-UHFFFAOYSA-N 0.000 description 1
- 229950006159 etersalate Drugs 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- FRQSLQPWXFAJFO-UHFFFAOYSA-N ethoxymethyl 2-(2,6-dichloro-3-methylanilino)benzoate Chemical compound CCOCOC(=O)C1=CC=CC=C1NC1=C(Cl)C=CC(C)=C1Cl FRQSLQPWXFAJFO-UHFFFAOYSA-N 0.000 description 1
- SEISMQVOJUJKGE-UHFFFAOYSA-M ethyl 1,6-dimethyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-1-ium-3-carboxylate;methyl sulfate Chemical compound COS([O-])(=O)=O.C1CCC(C)N2C(=O)C(C(=O)OCC)=C[N+](C)=C21 SEISMQVOJUJKGE-UHFFFAOYSA-M 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- GAWOVNGQYQVFLI-UHFFFAOYSA-N etoxazene Chemical compound C1=CC(OCC)=CC=C1N=NC1=CC=C(N)C=C1N GAWOVNGQYQVFLI-UHFFFAOYSA-N 0.000 description 1
- 229950008765 etoxazene Drugs 0.000 description 1
- 229950008467 euprocin Drugs 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- DOBLSWXRNYSVDC-UHFFFAOYSA-N fenalcomine Chemical compound C1=CC(C(O)CC)=CC=C1OCCNC(C)CC1=CC=CC=C1 DOBLSWXRNYSVDC-UHFFFAOYSA-N 0.000 description 1
- 229950009129 fenalcomine Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- ZEAJXCPGHPJVNP-UHFFFAOYSA-N fenyramidol Chemical compound C=1C=CC=CC=1C(O)CNC1=CC=CC=N1 ZEAJXCPGHPJVNP-UHFFFAOYSA-N 0.000 description 1
- 229960000555 fenyramidol Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- PRNNIHPVNFPWAH-UHFFFAOYSA-N fluoresone Chemical compound CCS(=O)(=O)C1=CC=C(F)C=C1 PRNNIHPVNFPWAH-UHFFFAOYSA-N 0.000 description 1
- 229950011300 fluoresone Drugs 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- ZWOUXWWGKJBAHQ-UHFFFAOYSA-N fluproquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=C(F)C=C1 ZWOUXWWGKJBAHQ-UHFFFAOYSA-N 0.000 description 1
- 229950004250 fluproquazone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229950010892 fosfosal Drugs 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- GWOFUCIGLDBNKM-UHFFFAOYSA-N glafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 GWOFUCIGLDBNKM-UHFFFAOYSA-N 0.000 description 1
- 229960001650 glafenine Drugs 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960004769 imidazole salicylate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- LZRDDINFIHUVCX-UHFFFAOYSA-N isofezolac Chemical compound OC(=O)CC1=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LZRDDINFIHUVCX-UHFFFAOYSA-N 0.000 description 1
- 229950004425 isofezolac Drugs 0.000 description 1
- WJDDCFNFNAHLAF-UHFFFAOYSA-N isonixin Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC=CNC1=O WJDDCFNFNAHLAF-UHFFFAOYSA-N 0.000 description 1
- 229950000248 isonixin Drugs 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- YEJZJVJJPVZXGX-MRXNPFEDSA-N lefetamine Chemical compound C([C@@H](N(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 YEJZJVJJPVZXGX-MRXNPFEDSA-N 0.000 description 1
- 229950008279 lefetamine Drugs 0.000 description 1
- MLHBDHJHNDJBLI-UHFFFAOYSA-N leucinocaine Chemical compound CCN(CC)C(CC(C)C)COC(=O)C1=CC=C(N)C=C1 MLHBDHJHNDJBLI-UHFFFAOYSA-N 0.000 description 1
- 229950006997 leucinocaine Drugs 0.000 description 1
- 229950003548 levoxadrol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- RBLKLJDYAHZCFW-UHFFFAOYSA-L magnesium;2-acetyloxybenzoate Chemical compound [Mg+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O RBLKLJDYAHZCFW-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229950007594 meprylcaine Drugs 0.000 description 1
- LJQWYEFHNLTPBZ-UHFFFAOYSA-N metabutoxycaine Chemical compound CCCCOC1=C(N)C=CC=C1C(=O)OCCN(CC)CC LJQWYEFHNLTPBZ-UHFFFAOYSA-N 0.000 description 1
- 229950004316 metabutoxycaine Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-XGUBFFRZSA-N methyl (1s,3s,4s,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-XGUBFFRZSA-N 0.000 description 1
- YBCPYHQFUMNOJG-UHFFFAOYSA-N metofoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C)C1CCC1=CC=C(Cl)C=C1 YBCPYHQFUMNOJG-UHFFFAOYSA-N 0.000 description 1
- 229950009818 metofoline Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960000429 mofezolac Drugs 0.000 description 1
- OOGNFQMTGRZRAB-UHFFFAOYSA-N morazone Chemical compound CC1C(C=2C=CC=CC=2)OCCN1CC(C1=O)=C(C)N(C)N1C1=CC=CC=C1 OOGNFQMTGRZRAB-UHFFFAOYSA-N 0.000 description 1
- 229960004610 morazone Drugs 0.000 description 1
- 229960002186 morpholine salicylate Drugs 0.000 description 1
- DVOUJRUFCBNRQW-UHFFFAOYSA-N mucoxin Chemical compound O1C(C(O)CCCCCCCCCCCCCCCCC)CC(O)C1C1OC(C(O)CCCCCC=2C(OC(C)C=2)=O)CC1 DVOUJRUFCBNRQW-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960000739 myrtecaine Drugs 0.000 description 1
- BZRYYBWNOUALTQ-HOTGVXAUSA-N myrtecaine Chemical compound CCN(CC)CCOCCC1=CC[C@@H]2C(C)(C)[C@H]1C2 BZRYYBWNOUALTQ-HOTGVXAUSA-N 0.000 description 1
- MSLICLMCQYQNPK-UHFFFAOYSA-N n-(4-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C=C1 MSLICLMCQYQNPK-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960002187 nifenazone Drugs 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- HKOURKRGAFKVFP-UHFFFAOYSA-N octacaine Chemical compound CCN(CC)C(C)CC(=O)NC1=CC=CC=C1 HKOURKRGAFKVFP-UHFFFAOYSA-N 0.000 description 1
- 229950009333 octacaine Drugs 0.000 description 1
- 229950006098 orthocaine Drugs 0.000 description 1
- 229960000986 oxetacaine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- DXHYQIJBUNRPJT-UHFFFAOYSA-N parsalmide Chemical compound CCCCNC(=O)C1=CC(N)=CC=C1OCC#C DXHYQIJBUNRPJT-UHFFFAOYSA-N 0.000 description 1
- 229950001060 parsalmide Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- XKFIQZCHJUUSBA-UHFFFAOYSA-N perisoxal Chemical compound C1=C(C=2C=CC=CC=2)ON=C1C(O)CN1CCCCC1 XKFIQZCHJUUSBA-UHFFFAOYSA-N 0.000 description 1
- 229950005491 perisoxal Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 description 1
- 229950007049 phenacaine Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- LQJARUQXWJSDFL-UHFFFAOYSA-N phenamine Chemical compound CCOC1=CC=C(NC(=O)CN)C=C1 LQJARUQXWJSDFL-UHFFFAOYSA-N 0.000 description 1
- 229950010879 phenamine Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229960003799 phenazopyridine hydrochloride Drugs 0.000 description 1
- PSBAIJVSCTZDDB-UHFFFAOYSA-N phenyl acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 PSBAIJVSCTZDDB-UHFFFAOYSA-N 0.000 description 1
- 229950009058 phenyl acetylsalicylate Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- XGNKHIPCARGLGS-UHFFFAOYSA-N pipebuzone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1(CCCC)CN1CCN(C)CC1 XGNKHIPCARGLGS-UHFFFAOYSA-N 0.000 description 1
- 229950004769 pipebuzone Drugs 0.000 description 1
- 229960001045 piperocaine Drugs 0.000 description 1
- 229950001532 piperylone Drugs 0.000 description 1
- BMIJYAZXNZEMLI-UHFFFAOYSA-N piridocaine Chemical compound NC1=CC=CC=C1C(=O)OCCC1NCCCC1 BMIJYAZXNZEMLI-UHFFFAOYSA-N 0.000 description 1
- 229950001038 piridocaine Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OPTZOXDYEFIPJZ-UHFFFAOYSA-N pronilide Chemical compound CCCOC1=CC=C([N+]([O-])=O)C=C1NC(C)=O OPTZOXDYEFIPJZ-UHFFFAOYSA-N 0.000 description 1
- QTGAJCQTLIRCFL-UHFFFAOYSA-N propacetamol Chemical compound CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1 QTGAJCQTLIRCFL-UHFFFAOYSA-N 0.000 description 1
- 229960003192 propacetamol Drugs 0.000 description 1
- 229950008865 propanocaine Drugs 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 1
- 229950011219 propipocaine Drugs 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- OYCGKECKIVYHTN-UHFFFAOYSA-N pyrrocaine Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCCC1 OYCGKECKIVYHTN-UHFFFAOYSA-N 0.000 description 1
- 229950000332 pyrrocaine Drugs 0.000 description 1
- 229960005038 quinisocaine Drugs 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 229950000385 ramifenazone Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229950001521 rimazolium metilsulfate Drugs 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical compound CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 229950009280 salacetamide Drugs 0.000 description 1
- RLISWLLILOTWGG-UHFFFAOYSA-N salamidacetic acid Chemical compound NC(=O)C1=CC=CC=C1OCC(O)=O RLISWLLILOTWGG-UHFFFAOYSA-N 0.000 description 1
- 229950000417 salamidacetic acid Drugs 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 229950001102 salicylsulfuric acid Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229950010729 salverine Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- IMOLVSPMDGCLMB-UHFFFAOYSA-N simetride Chemical compound COC1=CC(CCC)=CC=C1OCC(=O)N1CCN(C(=O)COC=2C(=CC(CCC)=CC=2)OC)CC1 IMOLVSPMDGCLMB-UHFFFAOYSA-N 0.000 description 1
- 229950007670 simetride Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229960005262 talniflumate Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229950002207 terofenamate Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 description 1
- 229950010298 tinoridine Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- UDKICLZCJWQTLS-UHFFFAOYSA-N tolycaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C(=O)OC UDKICLZCJWQTLS-UHFFFAOYSA-N 0.000 description 1
- 229950006609 tolycaine Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
- 229950002569 trimecaine Drugs 0.000 description 1
- UCCJWNPWWPJKGL-UHFFFAOYSA-N tropesin Chemical compound CC1=C(CC(=O)OCC(C(O)=O)C=2C=CC=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 UCCJWNPWWPJKGL-UHFFFAOYSA-N 0.000 description 1
- 229950002470 tropesin Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960002825 viminol Drugs 0.000 description 1
- ZILPIBYANAFGMS-UHFFFAOYSA-N viminol Chemical compound CCC(C)N(C(C)CC)CC(O)C1=CC=CN1CC1=CC=CC=C1Cl ZILPIBYANAFGMS-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- IYEPZNKOJZOGJG-UHFFFAOYSA-N xenbucin Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=CC=C1 IYEPZNKOJZOGJG-UHFFFAOYSA-N 0.000 description 1
- 229950005298 xenbucin Drugs 0.000 description 1
- 229960003434 xenysalate Drugs 0.000 description 1
- HLDCSYXMVXILQC-UHFFFAOYSA-N xenysalate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1O HLDCSYXMVXILQC-UHFFFAOYSA-N 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229940118827 zinc phenolsulfonate Drugs 0.000 description 1
- BOVNWDGXGNVNQD-UHFFFAOYSA-L zinc;2-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=CC=C1S([O-])(=O)=O.OC1=CC=CC=C1S([O-])(=O)=O BOVNWDGXGNVNQD-UHFFFAOYSA-L 0.000 description 1
- KYBJXENQEZJILU-UHFFFAOYSA-N zolamine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CS1 KYBJXENQEZJILU-UHFFFAOYSA-N 0.000 description 1
- 229950006211 zolamine Drugs 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
Definitions
- the present invention relates to an odorless formulation for treating mucosal discontinuities.
- the present invention also includes a method for making the formulation and a method for using the formulation.
- mucosal discontinuities refers to discontinuities which are present or which are inflicted on mucosal tissue of living beings. Mucosal discontinuities include wounds which are internal or external bodily injuries or lesions which are caused by a physical force or by another mechanism.
- the physical force is one or more of a mechanical, chemical, viral, bacterial, or thermally induced physical force. The physical force disrupts the normal continuities of biologic structures of living beings.
- Mucosal discontinuities include contusions, wounds in which the skin is unbroken, incisions, wounds in which the skin is broken by a cutting instrument, lacerations, and wounds in which the skin is broken by a dull or blunt instrument.
- Discontinuities include wounds caused by accident or by surgical procedures.
- Wound healing mechanisms comprise a series of processes whereby tissue, such as mucosal tissue, is repaired. In particular, in repair, specialized tissue is regenerated. New tissue is reorganized.
- Wound healing typically comprises three phases.
- a first phase is an inflammation phase that lasts up to about 3 days.
- a second phase is a cellular proliferation phase that lasts from about 3 to 12 days.
- a third phase is a remodeling phase that lasts from about 3 days to 6 months.
- platelet aggregation and clotting form a matrix which traps plasma proteins and blood cells to induce the influx of various type of cells.
- new connective or granulation tissue and blood vessels are formed.
- granulation tissue is replaced by a network of collagen and elastin fibers leading to the formation of scar tissue.
- the wound healing step is desirable to resuscitate the injured cells and to produce new cells to replace the dead cells.
- the healing process produces a reversal of cytotoxicity, a suppression of inflammation, and a stimulation of cellular viability and proliferation.
- Wounds typically require low levels of oxygen in the initial stages of healing to suppress oxidative damage and higher levels of oxygen in the later stages of healing to promote collagen formation by fibroblasts.
- aphthous ulcers One type of mucosal discontinuity includes aphthous ulcers. Aphthous ulcers are believed to be caused by a virus, in some instances, as well as genetics, trauma, hormonal changes, and gastrointestinal factors.
- Aphthous ulcers have shapes that range from single, multiple, round, to oval shaped.
- the ulcers range in size from 2-40 mm.
- the ulcers occur on mucus membranes of the tongue, cheeks, lips, soft and hard pallets, gingiva, pharynx and on the floor of the mouth.
- the ulcers are also found in the genital, anal, and in conjunctival mucosae.
- Aphthous ulcers are extremely painful lesions.
- the ulcers appear as small macular red lesions.
- the ulcerated area quickly undergoes necrosis, leaving a sharply defined rounded ulcer, varying from about 2 to 5 mm in diameter.
- the ulceration is fairly deep with a yellow white base representing the tissue at the surface.
- the margin of the ulcer somewhat indurated and the margin of the mucosae has a surrounding erythematous zone.
- the marginal erythema ranges from slight to extensive, depending upon the degree of the secondary bacterial involvement.
- the aphthous ulcer is present for about seven days and it undergoes gradual healing. It heals as a general rule in approximately 10-14 days and does not tend to leave a scar. Characteristically, there is a recurrent pattern of one of more of these ulcers. The ulcers recur as soon as one month apart and there are cases where, for a period of years, the individual is never without ulcers. New ulcers form as the existing lesions heal. In other cases, aphthous ulcer attacks may occur two to three times during a year. The lesions also often appear following some intense emotional stress, but they may first appear following a gradual change in environment or following an emotional situation in a non-familiar environment.
- Periadenitis Mucosa Necrotica Recurrens is sometimes used to describe aphthae that coalesce to form an elongated, deep ulcerated area. From a symptomatic standpoint, it has found that about 24-48 hrs. before onset of an aphthous lesion, there is a vague discomfort, sometimes described as a tingling sensation in the area. As the tissue undergoes necrosis and an ulcer forms, the lesions become very painful. The aphthous lesions are often considered the most painful oral ulcerations. The discomfort may become particularly intense during periods of fatigue.
- the histopathology of the disease is one where the microscopy picture is non-specific, generally showing an ulceration of the mucosae.
- the surface epithelium exhibits a central area of destruction.
- the connective tissue is densely infiltrated with lymphocytes, polymorphonuclear leukocytes, plasma cells, and histocytes. There is evidence of active fibrosis at the base and sides of the ulcerated area.
- Differential diagnosis of aphthous ulcers includes traumatic ulcers, acute herpetic stomatitis, stomatitis medicamentosa, and erythema multiforme.
- the diagnosis of aphthous stomatitis is based upon the clinical manifestation and the patient's history. Biopsies are usually unnecessary due the extreme discomfort involved and are avoided unless necessary to rule out other lesions considered differentially diagnostic.
- cauterizing drugs such as phenol, chromic acid, alum and silver nitrate
- These agents alleviate pain by destruction of small nerve endings.
- the healing time of the lesion is prolonged due to the escharotic action of these drugs on the surface epithelium and the active fibrosis at the base and sides of the ulcerated areas.
- Vitamins have also been tried with inconsistent results.
- Antibiotics have been used with conflicting results.
- U.S. Pat. Nos. 3,920,835, 3,984,556, and 3,988,470 all issued to Van Scott et al., disclose methods for treating acne, dandruff and palmar keratosis, respectively.
- the methods generally comprise applying to an affected area a topical composition that comprises about 1% to 20% of a lower aliphatic compound composition that contains from 2 to 6 carbon atoms selected from a group consisting of alpha hydroxy acid, alpha-ketoacids and esters thereof, and 3-hydroxybutyric acid in a pharmaceutically acceptable carrier.
- U.S. Pat. No. 4,416,982 issued to Tauda et al. discloses a method for decomposing hydrogen peroxide by reacting the hydrogen peroxide with a phenol or aniline derivative in the presence of peroxidase.
- One prior art formulation is manufactured by Northern Research Laboratories of St. Paul, Minn.
- the formulation is a reddish-brown material that has a strong phenolic odor.
- FIG. 1 a is a schematic view of a prior art formulation that includes sulfuric acid, Beechwood creosote and purified water.
- FIG. 1 b is a schematic view of the formulation of the present invention and its uses in treating conditions of skin and the oral cavity.
- FIG. 2 is a formula view of chemicals in the formulation of the present invention.
- FIG. 3 is a description of attributes of the formulation of the present invention.
- FIGS. 4-6 are descriptions of the attributes of the formulation of the present invention used to treat specified skin conditions.
- FIG. 7 is a perspective view of devices for application of the formulation of the present invention.
- One embodiment of the present invention includes a method for making an array of formulations tailored for treating specific types of mucosal discontinuities.
- the method includes providing phenol, guaiacol, sulfuric acid and, optionally, water in preselected concentrations; reacting the guaiacol and phenol with the sulfuric acid and water to make phenolsulfonic acid and guaiacolsulfonic acid and, for some embodiments, free water and free acid to produce a formulation having a preselected concentration of preselected isomers of phenolsulfonic acid, preselected isomers of guaiacolsulfonic acid, and optionally, free acid and free water.
- Another embodiment of the present invention includes a formulation for treating mucosal discontinuities, comprising: phenolsulfonic acid and isomers of phenolsulfonic acid; guaiacolsulfonic acid and isomers of guaiacolsulfonic acid and mono- and bis-forms of guaiacolsulfonic acid; ammonium phenolsulfonate; and potassium guaiacolsulfonate.
- Another embodiment of the present invention includes a formulation for treating oral mucosal discontinuities, comprising: phenolsulfonic acid in a concentration of 25-80% by weight; guaiacolsulfonic acid in a concentration of 25-80% by weight; free sulfuric acid in a concentration of 13 to 32% by weight; and water in a concentration of 0 to 3% by weight.
- One other embodiment includes a formulation for treating skin mucosal discontinuities, comprising: phenolsulfonic acid in a concentration of 25-80% by weight; ammonium phenolsulfonate in a concentration of 0 to 5% by weight; guaiacolsulfonic acid in a concentration of 25-80% by weight; free sulfuric acid in a concentration of 0 to 32% by weight; and water in a concentration of 0 to 3% by weight.
- Another embodiment includes a device for treating mucosal discontinuities, comprising: a syringe, and the formulation of the present invention contained in the syringe.
- One other embodiment of the present invention includes a system comprising: ingredients that include phenolsulfonic acid, guaiacolsulfonic acid, ammonium phenolsulfonate, potassium guaiacolsulfonate, water and free acid; and a mechanism calibrated to mix preselected amounts of two or more of the ingredients together to make a formulation for treating a specific type of mucosal discontinuity.
- the present invention includes a method and system for making an array of formulations tailored for treating specific types of mucosal discontinuities.
- the method includes providing phenol, guaiacol, sulfuric acid and, optionally, water, and reacting the guaiacol and phenol with the sulfuric acid and, optionally, water to make phenolsulfonic acid and guaiacolsulfonic acid and, for some embodiments, free water and free acid.
- the preselected concentrations of guaiacol, phenol, sulfuric acid, free acid and water produce a formulation having a preselected concentration of four isomers of phenolsulfonic acid, seven isomers of guaiacolsulfonic acid, and for some embodiments, free acid and free water.
- the specific isomer concentrations and concentration ratios are preselected by selecting specific reaction parameters such as time, temperature, and concentration of reactants that produce the preselected isomer concentration profile.
- the phenolsulfonic acid is further treated with a hydroxide such as ammonium hydroxide to make ammonium phenolsulfonate.
- a hydroxide such as ammonium hydroxide to make ammonium phenolsulfonate.
- the guaiacolsulfonic acid is treated with a hydroxide such as potassium or zinc hydroxide to make potassium guaiacolsulfonate.
- the system of the present invention includes the ingredients phenolsulfonic acid, guaiacolsulfonic acid, sulfosalicylic acid, ammonium phenolsulfonate, potassium guaiacolsulfonate, water and sulfuric acid which is National Formulary (NF).
- the system also includes a mechanism calibrated to mix preselected amounts of the ingredients together to make a formulation for treating a specific type of mucosal discontinuity.
- the term “mucosal discontinuity” refers to lesions, ulceration, or inflammation on the moist linings of the buccal cavity, nasal cavity, gastrointestinal tract, respiratory tract, conjunctiva, vagina, colon, urinary bladder, and urethra (Forstner et al., 1973 J. Cell. Sci. 12:585; Peppas et al., 1985 J. Control. Release 2:257; Lehr et al., 1992 J. Control Release 18:249; Spiro, 1970 Ann. Rev. Biochem. 39:599; Lebat-Robert et al., 1979 Path. Biol. 24:241).
- a formulation for treating gingivitis, one type of mucosal discontinuity includes sulfonic acid and little or no free acid.
- phenolsulfonic acids and guaiacolsulfonic acids in a formulation with free sulfuric acid are used to treat periodontal disease, another type of mucosal discontinuity.
- a formulation that includes phenolsulfonic acid, sulfosalicylic acid, and guaiacolsulfonic acid with no free acid is usable as a facial exfoliant or as a treatment for canker sores.
- a formulation that includes phenolsulfonic acid, sulfosalicylic acid, phenolsulfonate, and free acid is usable as a skin exfoliant for use on feet.
- the present invention includes a formulation for treating mucosal discontinuities that includes phenolsulfonic acid, sulfosalicylic acid, guaiacolsulfonic acid, and, for some embodiments, ammonium phenolsulfonate, free sulfuric acid and water.
- the formulation includes phenolic compounds that are isolated and purified, as is shown in FIG. 1B .
- the purified phenolic compounds are shown in FIG. 2 and include phenol, guaiacol, salicylic acid, resorcinol and hydroquinone.
- the purified phenolics are treated with sulfuric acid to form sulfonic acids and sulfonate salts, as is shown in FIG. 1B .
- the sulfonate salts are treated with one or more of zinc, potassium and sodium to form a salt. Examples of other salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
- Phenolic compounds obtained from a variety of sources are usable to make the formulation of the present invention
- Formulations that include the sulfonic acids of phenol and guaiacol are used to treat mucosal discontinuities in the oral cavity such as aphthous stomatitis, canker sores, chronic periodontitis and gingivitis.
- Formulations that include the sulfonate salts of phenol and guaiacol are used to treat mucosal discontinuities of the skin, such as dermatologic disorders.
- Formulations that include the phenolsulfonate salts also have use as skin resurfacing products. A breakdown of these acid and salt products is shown in FIG. 2 .
- the reaction products When phenol is treated with sulfuric acid, the reaction products include four isomers of phenolsulfonic acid.
- the reaction products When guaiacol is treated with sulfuric acid, the reaction products include seven isomers, a mono- and a bis-form of guaiacolsulfonic acid.
- Other sources of phenolsulfonic acid include the four isomers.
- Other sources of guaicol include the seven isomers, a mono- and a bis-form of guaiacolsulfonic acid.
- the method and system of the present invention is a significant improvement over methods and systems used to make formulations prepared with Beechwood creosote because the method, system, and formulations of the present invention do not have the intense phenolic odor and taste of prior art products. Furthermore, the efficacy of the formulations of the present invention is very high because the acids and salts are separated from Beechwood creosote and from each other or are synthesized in a process that does not require Beechwood creosote and are systematically and specifically blended in amounts that are targeted to treat the oral cavity and the skin, respectively.
- the formulation composition includes phenolsulfonic acid in a concentration of 30 percent by weight; guaiacolsulfonic acid in a concentration of 32 percent by weight; free sulfuric acid in a concentration of 24 percent by weight; water in a concentration of 11.9 percent by weight; and FD&C Red No. 40 in a concentration of 0.075 percent by weight.
- This formulation has a density of 1.59 g/mL, a total acidity of 9.1 mM/g, and a viscosity of 1025 cPs at 25 degrees Centigrade.
- the formulation is applied with an applicator.
- the application contact time for treatment of periodontal disease is 5 to 30 seconds per infected tooth pocket.
- the applicator is a pre-filled syringe.
- the applicator is a kit that includes a topical anesthetic and an application device such as the pre-filled syringe.
- the topical local anesthetic is applied with any conventional applicator such as a cotton swab.
- the term “local anesthetic” means any drug that provides local numbness or analgesia or any drug that provides a regional blockage of nociceptive pathways (afferent and/or efferent) and that is not an agonist or an antagonist of an opioid receptors.
- the local anesthetic can be any local anesthetic known or to be developed.
- Examples of local anesthetics suitable for use with the invention include: ambucaine, amolanone, amylcaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethisoquin, dimethocaine, diperodon, dyclonine, ecogonidine, ecogonine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxyteteracaine, isobutyl p-aminobenzoate, leucinocaine, levoxadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloride, my
- kits and formulation embodiments include an analgesic.
- suitable analgesics include, but are not limited to, aceclofenac, acetaminophen, acetaminosalol, acetanilide, acetylsalicylsalicylic acid, alclofenac, alminoprofen, aloxiprin, aluminum bis(acetylsalicylate), aminochlorthenoxazin, 2-amino-4-picoline, aminopropylon, aminopyrine, ammonium salicylate, amtohnetin guacil, antipyrine, antipyrine salicylate, antrafenine, apazone, aspirin, benorylate, benoxaprofen, benzpiperylon, benzydamine, bermoprofen, bromfenac, p-bromoacetanilide, 5-bromosalicylic acid acetate, bucetin, bufexamac, bumadizon, butacetin, calcium
- Acceptable component ranges for a formulation for treating mucosal discontinuities of the oral cavity, such as gingivitis are as follows: Component Concentration Ranges Phenolsulfonic Acid 25-80% by weight Guaiacolsulfonic Acid 25-80% by weight Sulfosalicylic Acid 0-30% by weight Citric Acid 0-30% by weight Ammonium Phenolsulfonate 0-32% by weight Free Sulfuric Acid 0-32% by weight Water 13-30% by weight
- Acceptable component ranges for a formulation for treating mucosal discontinuities of the skin are as follows: Component Concentration Ranges Phenolsulfonic Acid 25-80% by weight Guaiacolsulfonic Acid 25-80% by weight Ammonium Phenolsulfonate 0-5% by weight Free Sulfuric Acid 0-3% by weight Water 0-30% by weight Colorant 0.075-0.020% by weight
- These mucosal discontinuities include sores such as canker sores.
- Another formulation embodiment of the present invention is for treatment of periodontal disease.
- Acceptable concentration ranges are as follows: Component Concentration Ranges Phenolsulfonic Acid 25 to 80% Guaiacolsulfonic Acid 25 to 80% Ammonium Phenolsulfonate 0 to 32% Free Sulfuric Acid 0 to 32% Water 0 to 30% Colorant 0.00 to 0.075%
- the viscosity is 70 to 1000 cPs.
- the total acidity is 7.20 to 9.20 mM/g.
- the density is 1.46 to 1.59 g/mL.
- the application time is 5 to at least 60 seconds.
- the applicator includes in some embodiments, a vial, a pre-filled syringe, or a swab or combinations of these applicators.
- the formulation optionally includes a colorant such as green or blue.
- the formulation of the present invention has use as a liquid chemical cauterization agent for, in one embodiment, the oral cavity mucosa.
- the mechanisms of therapeutic action include solvent and keratolytic-based mechanisms that include penetrating and dissolving necrotic tissues.
- the mechanism also includes hygroscopic and dehydrating-based mechanisms.
- the formulation reduces tissue edema.
- the solvation is exothermic.
- the solvation releases acidification.
- the mechanism is also a denaturant and keratocoagulant-based.
- the formulation causes acidification necrosis and oxidation.
- the formulation also aids in generation of a surrogate Eschar/clot that acts as a protective natural bandage.
- the formulation of the present invention provides instantaneous pain relief to a user and accelerates ulcer healing.
- the formulation kills infectious organisms and is effective in a single application applied to an ulcer or other mucosal discontinuity.
- the formulation of the present invention is self-limited and is not harmful to healthy mucosa.
- the reaction of the formulation is limited by water solvation, barrier membrane formation, and acid neutralization.
- FIG. 7 Devices for applying the formulations of the present invention are shown in FIG. 7 and include a syringe and a cotton swab.
- the syringe is prefilled.
- the formulation of the present invention is enclosed within a swab device.
- the formulation is enclosed in a container with a delivery mechanism that delivers the formulation drop-by-drop.
- the formulation is metered.
- the formulation is enclosed in a container that includes a mechanism for heating or cooling the formulation.
- the mechanism includes chemicals, separated in compartments by a breakable seal, adjacent to the formulation of the present invention, that create either an exothermic or endothermic reaction when combined.
- the chemicals are separated from the formulation by a wall.
- the chemicals are combined when a user breaks the breakable seal.
- the heating or cooling is transferred to the formulation through the wall.
- the packaged formulation of the present invention is transported for sale to pharmacies and drug stores.
- the formulation of the present invention is packaged with an anesthetic.
- the anesthetic is applied to the mucosal discontinuity first.
- one embodiment of the present invention includes a method for preparing treatments for mucosal discontinuities in the oral cavity and skin.
- One method embodiment is described in the following example:
- Phenolsulfonic acid solution was prepared in sulfuric acid.
- the method included setting up a recirculating water bath so that the water was at a temperature of 95 degrees Centigrade.
- the weight of available stock of Liquified Phenol USP containing 3.23 moles of Phenol was calculated.
- Phenol has a molecular weight of 94.11.
- the weight of 3.23 moles of Phenol is 3.23 ⁇ 94.11+303.97 grams.
- the purity of Liquified Phenol USP typically ranges from 89.0% to 91.5%. Using the purity value either from the manufacturer's Certificate of Analysis or the purity value from an internal quality control analysis, the weight of the available stock of Liquified Phenol USP required to deliver 3.23 moles of Phenol was calculated.
- the amount of available stock sulfuric acid (NF) that contains 7.08 moles was calculated.
- the purity of sulfuric acid NF typically ranges from 95.0% to 98%.
- a 1 liter Corning Pyrex Bottle No. 1395 was placed on a Mettler PG-5002-S balance.
- a 600 mL beaker was filled with about 400 mL of Liquified Phenol USP from the stock bottle.
- a quantity of 3.23 moles of phenol as liquified phenol USP by weight was added from the beaker using the weight of available stock.
- the amount of liquid phenol was calculated to provide 3.23 moles of phenol.
- a 5 cm magnetic stirring bar was placed in the bottle containing the phenol/sulfuric acid mixture.
- the bottle and mixture were enclosed with a standard Corning low-temperature closure, placed on the bottle.
- the mixture was mixed on a magnetic stir plate for thirty minutes.
- the bottle was placed in a pre-heated 95 degrees Centigrade recirculating water bath for 14 to 24 hours.
- the bottle was removed from the water bath after 14 to 24 hours.
- the bottle was allowed to cool to room temperature and an identifying sticker was applied.
- a solution of guaiacolsulfonic acid in sulfuric acid was prepared. Water in the recirculating water bath was heated to 65 degrees Centigrade. The weight of available stock guaiacol, purified reagent, that contained 1.63 moles of guaiacol was calculated. The amount of available stock of sulfuric acid NF that contained 3.41 moles of sulfuric acid was calculated. A 1 liter Corning Pyrix bottle No. 1395 was placed on the Mettler PG-5002-S balance. A 600 mL beaker was filled with approximately 400 mL guaiacol, purified reagent from the available stock bottle. A quantity of 1.63 moles of guaiacol as guaiacol, purified reagent by weight from the beaker was added to the bottle.
- a 5 cm magnetic stir bar was placed in the bottom of the Pyrex bottle.
- the bottle was placed on a magnetic stir plate and stirred at low speed.
- a ring stand was placed next to the stir plate.
- a thermometer was mounted onto the ring stand so that the tip of the thermometer was positioned in the guaiacol.
- a 250 mL cylinder was also mounted onto the ring stand so that the tip was inserted into the opening of the Pyrex bottle.
- a 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF.
- a second 600 mL beaker was placed on the Mettler PG-5002-S balance.
- a quantity of 3.41 moles of sulfuric acid as stock sulfuric acid NF was added to the second beaker.
- the cylinder stopcock With the cylinder stopcock in the closed position, the weighed amount of sulfuric acid NF was transferred from the second beaker to the addition cylinder mounted above the Pyrex bottle containing the measured quantity of guaiacol.
- the sulfuric acid was added from the addition cylinder to the guaiacol in the bottle in 10 to 20 mL aliquots while maintaining steady stirring.
- the temperature of the mixture was monitored to maintain a range of 55 to 65 degrees Centigrade until all of the acid was placed in the bottle.
- the reaction mixture was stirred for 30 minutes after all of the sulfuric acid was added to the mixture.
- the mixture was enclosed by a standard Corning low temperature closure on the bottle.
- the bottle was placed in a pre-heated 65 degrees Centigrade recirculating water bath for 14 to 24 hours. The bottle was removed after the 14 to 24 hours and allowed to come to room temperature. The bottle was then marked.
- the phenolsulfonic acid solution and the guaiacolsulfonic acid solution were then subjected to quality control. After being release by Quality Control, 1000 grams of the phenolsulfonic acid solution and 500 grams of the guaiacolsulfonic acid solution were prepared in a 2 liter Corning Pyrix bottle No. 1395 using the Mettler PG-5002-S balance. A quantity of 1.125 grams of FD&C Red #40 powdered colorant was weighed and added to the phenolsulfonic/guaiacolsulfonic mixture. The bottle was mixed by inverting repeatedly until the color was evenly dispersed. The colored phenolsulfonic/guaiacolsulfonic mixture was then available for use.
- a facial exfoliant was prepared.
- a solution of phenolsulfonic acid was prepared as described in Example 1, except that the weight of available stock liquefied phenol USP was calculated and prepared for 4.0 moles of phenol.
- the amount of available stock sulfuric acid NF that contained 4.0 moles was calculated.
- the weight of sulfuric acid NF was 392.32 grams.
- the 4.0 moles of sulfuric acid NF was treated as described in Example 1.
- a quantity of 400 mL of Liquified Phenol USP was added to a 600 mL beaker.
- a quantity of 4.0 moles of phenol as Liquefied Phenol USP was added to a 1 L Corning Pyrex No. 1395 bottle using the Mettler PS-5002-S balance.
- a second 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF.
- stock sulfuric acid NF was added to the bottle.
- a 5 cm magnetic stirring bar was placed in a bottle containing the phenol/sulfuric acid mixture and enclosed with a Corning low-temperature closure. The solution was mixed for 30 minutes. The bottle was then placed in a pre-heated 95 degree Centigrade recirculating water bath for 14 to 24 hours. After 14 to 24 hours, the bottle was removed and allowed to come to room temperature and marked with a sticker.
- the weight of available stock guaiacol, purified reagent that contained 3.50 moles of guaiacol was calculated.
- the amount of available stock sulfuric acid NF that contained 3.50 moles of sulfuric acid was also calculated.
- a 1 L Corning Pyrex bottle No. 1395 was placed on the Mettler PG-5002-S balance.
- a 600 mL beaker was filled with approximately 400 mL of guaiacol, purified reagent.
- a quantity of 3.50 moles of guaiacol was added from the beaker to the 1 L Pyrex bottle.
- a quantity of 3.50 moles of sulfuric acid NF was added to the 1 L Pyrex bottle, as described in Example 1, in 10 to 20 mL aliquots while maintaining steady stirring between 55 to 65 degrees Centigrade until all of the acid had been placed in the bottle.
- the mixture was continuously stirred for 30 minutes after all of the sulfuric acid has been added and a Corning low temperature closure was placed on the bottle.
- the bottle was placed in a pre-heated 65 degree Centigrade recirculating water bath for 14 to 24 hours. The bottle was removed from the water bath after 14 to 24 hours. The bottle was allowed to come to room temperature and was then marked for quality control.
- a quantity of 750 grams of the phenolsulfonic acid solution and 750 grams of the guaiacolsulfonic acid solution were combined in a 2 L Corning Pyrex bottle.
- a quantity of 1.5 grams of Citronellal fragrance was added. The acids were mixed by inverting the bottle repeatedly until evenly blended.
- the method also includes treating the purified phenolics with sulfuric acid to make sulfonic acids and sulfonate salts.
- the method further includes using the sulfonic acids to treat mucosal discontinuities in the oral cavity such as aphthous stomatitis, chronic periodontitis, canker sores, and gingivitis.
- the method includes using the sulfonate salts to treat dermatologic disorders and for skin resurfacing.
- a skin exfoliant for use on feet was prepared.
- a solution of phenolsulfonic acid was prepared as described in Example 1, except that the weight of available stock liquefied phenol USP was calculated and prepared for 5.0 moles of phenol.
- the amount of available stock sulfuric acid NF that contained 5.0 moles was calculated.
- the weight of sulfuric acid NF was 490.4 grams.
- the 5.0 moles of sulfuric acid NF was treated as described in Example 1.
- a quantity of 470.55 gms of Liquified Phenol USP was added to a 600 mL beaker.
- a quantity of 5.0 moles of phenol as Liquefied Phenol USP was added to a 1 L Corning Pyrex No. 1395 bottle using the Mettler PS-5002-S balance.
- a second 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF.
- stock sulfuric acid NF was added to the bottle.
- a 5 cm magnetic stirring bar was placed in a bottle containing the phenol/sulfuric acid mixture and was enclosed with a Corning low-temperature closure. The solution was mixed for 30 minutes. The bottle was then placed in a pre-heated 95 degree Centigrade recirculating water bath for 14 to 24 hours. After 14 to 24 hours, the bottle was removed and was allowed to come to room temperature and marked with a sticker.
- the phenolsulfonic acid and beaker were placed on the Mettler balance. A quantity of 300 grams of reagent grade ammonium phenolsulfonate was added to the phenolsulfonic acid. A quantity of 30 grams of reagent grade zinc phenolsulfonate was added to the phenolsulfonic acid. A quantity of 1.5 grams of Citronellal fragrance was added. The acids were mixed by vigorous stirring using a power hand blender.
- a treatment for canker sores was formulated.
- a solution of phenolsulfonic acid was prepared as described in Example 1, except that the weight of available stock liquefied phenol USP was calculated and prepared for 2.4 moles of phenol.
- the amount of available stock sulfuric acid NF that contained 5.26 moles was calculated.
- the weight of sulfuric acid NF was 515.90 grams.
- the 5.26 moles of sulfuric acid NF was treated as described in Example 1.
- a quantity of 400 mL of Liquified Phenol USP was added to a 600 mL beaker.
- a quantity of 2.4 moles of phenol as Liquefied Phenol USP was added to a 1 L Corning Pyrex No. 1395 bottle using the Mettler PS-5002-S balance.
- a second 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF.
- stock sulfuric acid NF was added to the bottle.
- a 5 cm magnetic stirring bar was placed in a bottle containing the phenol/sulfuric acid mixture and enclosed with a Corning low-temperature closure. The solution was mixed for 30 minutes. The bottle was then placed in a pre-heated 95 degree Centigrade recirculating water bath for 14 to 24 hours. After 14 to 24 hours, the bottle was removed and allowed to come to room temperature and marked with a sticker.
- the weight of available stock guaiacol, purified reagent that contains 2.3 moles of guaiacol was calculated.
- the amount of available stock sulfuric acid NF that contains 4.82 moles of sulfuric acid was also calculated.
- a 1 L Corning Pyrex bottle No. 1395 was placed on the Mettler PG-5002-S balance.
- a 600 mL beaker was filled with approximately 400 mL of guaiacol, purified reagent.
- a quantity of 2.3 moles of guaiacol was added from the beaker to the 1 L Pyrex bottle.
- a quantity of 4.82 moles of sulfuric acid NF was added to the 1 L Pyrex bottle, as described in Example 1, in 10 to 20 mL aliquots while maintaining steady stirring between 55 to 65 degrees Centigrade until all of the acid had been placed in the bottle. Stirring was continued for 30 minutes after all of the sulfuric acid has been added and a Corning low temperature closure was placed on the bottle.
- the bottle was placed in a pre-heated 65 degree Centigrade recirculating water bath for 14 to 24 hours. The bottle was removed from the water bath after 14 to 24 hours. The bottle was allowed to come to room temperature and then was marked for quality control.
- a quantity of 750 grams of the phenolsulfonic acid solution and 750 grams of the guaiacolsulfonic acid solution were combined in a 2 L Corning Pyrex bottle.
- a quantity of 1.5 grams of Citronellal fragrance was added. The acids were mixed by inverting the bottle repeatedly until evenly blended.
- the method also includes treating the purified phenolics with sulfuric acid to make sulfonic acids and sulfonate salts.
- the method further includes using the sulfonic acids to treat mucosal discontinuities in the oral cavity such as aphthous stomatitis, chronic periodontitis and gingivitis.
- the method includes using the sulfonate salts to treat dermatologic disorders and for skin resurfacing.
Abstract
The present invention includes a method for making a formulation for treating mucosal discontinuities, comprising: providing phenolic compounds and treating the purified phenolic compounds with sulfuric acid to make sulfonic acids and sulfonate salts. The present invention also includes formulations prepared by the method.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/443,446, filed May 21, 2003, which claims priority under 35 U.S.C. 119(e) from U.S. provisional application 60/437,777 filed Jan. 3, 2003, which applications are incorporated herein by reference.
- Reference is made to the following commonly assigned application entitled as follows: METHOD FOR EXFOLIATING SKIN. The above-identified Application is being filed on May 21, 2003, the same filing date as the instant application.
- The present invention relates to an odorless formulation for treating mucosal discontinuities. The present invention also includes a method for making the formulation and a method for using the formulation.
- The term, “mucosal discontinuities” as used herein refers to discontinuities which are present or which are inflicted on mucosal tissue of living beings. Mucosal discontinuities include wounds which are internal or external bodily injuries or lesions which are caused by a physical force or by another mechanism. The physical force is one or more of a mechanical, chemical, viral, bacterial, or thermally induced physical force. The physical force disrupts the normal continuities of biologic structures of living beings.
- Mucosal discontinuities include contusions, wounds in which the skin is unbroken, incisions, wounds in which the skin is broken by a cutting instrument, lacerations, and wounds in which the skin is broken by a dull or blunt instrument. Discontinuities include wounds caused by accident or by surgical procedures.
- Patients who suffer major wounds and other discontinuities benefit from treatment that enhances healing and pain relief. Wound healing mechanisms comprise a series of processes whereby tissue, such as mucosal tissue, is repaired. In particular, in repair, specialized tissue is regenerated. New tissue is reorganized.
- Wound healing typically comprises three phases. A first phase is an inflammation phase that lasts up to about 3 days. A second phase is a cellular proliferation phase that lasts from about 3 to 12 days. A third phase is a remodeling phase that lasts from about 3 days to 6 months.
- During the first inflammation phase, platelet aggregation and clotting form a matrix which traps plasma proteins and blood cells to induce the influx of various type of cells. During the second cellular proliferation phase, new connective or granulation tissue and blood vessels are formed. During the third remodeling phase, granulation tissue is replaced by a network of collagen and elastin fibers leading to the formation of scar tissue.
- When cells are injured or killed as a result of a wound, the wound healing step is desirable to resuscitate the injured cells and to produce new cells to replace the dead cells. The healing process produces a reversal of cytotoxicity, a suppression of inflammation, and a stimulation of cellular viability and proliferation. Wounds typically require low levels of oxygen in the initial stages of healing to suppress oxidative damage and higher levels of oxygen in the later stages of healing to promote collagen formation by fibroblasts.
- One type of mucosal discontinuity includes aphthous ulcers. Aphthous ulcers are believed to be caused by a virus, in some instances, as well as genetics, trauma, hormonal changes, and gastrointestinal factors.
- Aphthous ulcers have shapes that range from single, multiple, round, to oval shaped. The ulcers range in size from 2-40 mm. The ulcers occur on mucus membranes of the tongue, cheeks, lips, soft and hard pallets, gingiva, pharynx and on the floor of the mouth. The ulcers are also found in the genital, anal, and in conjunctival mucosae.
- Aphthous ulcers are extremely painful lesions. The ulcers appear as small macular red lesions. The ulcerated area quickly undergoes necrosis, leaving a sharply defined rounded ulcer, varying from about 2 to 5 mm in diameter. The ulceration is fairly deep with a yellow white base representing the tissue at the surface. The margin of the ulcer somewhat indurated and the margin of the mucosae has a surrounding erythematous zone. The marginal erythema ranges from slight to extensive, depending upon the degree of the secondary bacterial involvement.
- The aphthous ulcer is present for about seven days and it undergoes gradual healing. It heals as a general rule in approximately 10-14 days and does not tend to leave a scar. Characteristically, there is a recurrent pattern of one of more of these ulcers. The ulcers recur as soon as one month apart and there are cases where, for a period of years, the individual is never without ulcers. New ulcers form as the existing lesions heal. In other cases, aphthous ulcer attacks may occur two to three times during a year. The lesions also often appear following some intense emotional stress, but they may first appear following a gradual change in environment or following an emotional situation in a non-familiar environment.
- Aphthous ulcers have been found to occur in greater frequency in women. The ulcers appear several days prior to the menstrual period. The first encounter with aphthous stomatitis for women frequently follows the onset of menstruation. Women susceptible to these lesions often report freedom from the lesions during pregnancy. There is a tendency for a greater frequency of these lesions in females than in males. Although they occur at any age level, the ulcers occur more often in adults.
- The term “Periadenitis Mucosa Necrotica Recurrens” is sometimes used to describe aphthae that coalesce to form an elongated, deep ulcerated area. From a symptomatic standpoint, it has found that about 24-48 hrs. before onset of an aphthous lesion, there is a vague discomfort, sometimes described as a tingling sensation in the area. As the tissue undergoes necrosis and an ulcer forms, the lesions become very painful. The aphthous lesions are often considered the most painful oral ulcerations. The discomfort may become particularly intense during periods of fatigue.
- The histopathology of the disease is one where the microscopy picture is non-specific, generally showing an ulceration of the mucosae. The surface epithelium exhibits a central area of destruction. The connective tissue is densely infiltrated with lymphocytes, polymorphonuclear leukocytes, plasma cells, and histocytes. There is evidence of active fibrosis at the base and sides of the ulcerated area.
- Differential diagnosis of aphthous ulcers includes traumatic ulcers, acute herpetic stomatitis, stomatitis medicamentosa, and erythema multiforme. The diagnosis of aphthous stomatitis is based upon the clinical manifestation and the patient's history. Biopsies are usually unnecessary due the extreme discomfort involved and are avoided unless necessary to rule out other lesions considered differentially diagnostic.
- Many substances in agents have been used in an attempt to cure and or relieve the discomfort of aphthous lesion. For example, cauterizing drugs, such as phenol, chromic acid, alum and silver nitrate, have been used for many years. These agents alleviate pain by destruction of small nerve endings. The healing time of the lesion is prolonged due to the escharotic action of these drugs on the surface epithelium and the active fibrosis at the base and sides of the ulcerated areas. Vitamins have also been tried with inconsistent results. Antibiotics have been used with conflicting results.
- One observer found that Aureomycin applied locally, three times a day appeared to have a definite effect. With treatment, the duration of the ulcers was reduced from about 10-5 days and there was an analgesic effect lasting one half to two hours. Temporary relief has also been sought and sometimes achieved by using milk of magnesia or heavy syrups. Other more exotic remedies have been tried with little or no success. These remedies include vaccination with cowpox virus, and nutrient supplements.
- U.S. Pat. Nos. 3,920,835, 3,984,556, and 3,988,470, all issued to Van Scott et al., disclose methods for treating acne, dandruff and palmar keratosis, respectively. The methods generally comprise applying to an affected area a topical composition that comprises about 1% to 20% of a lower aliphatic compound composition that contains from 2 to 6 carbon atoms selected from a group consisting of alpha hydroxy acid, alpha-ketoacids and esters thereof, and 3-hydroxybutyric acid in a pharmaceutically acceptable carrier.
- U.S. Pat. No. 4,416,982 issued to Tauda et al. discloses a method for decomposing hydrogen peroxide by reacting the hydrogen peroxide with a phenol or aniline derivative in the presence of peroxidase.
- One prior art formulation is manufactured by Northern Research Laboratories of St. Paul, Minn. The formulation is a reddish-brown material that has a strong phenolic odor.
-
FIG. 1 a is a schematic view of a prior art formulation that includes sulfuric acid, Beechwood creosote and purified water. -
FIG. 1 b is a schematic view of the formulation of the present invention and its uses in treating conditions of skin and the oral cavity. -
FIG. 2 is a formula view of chemicals in the formulation of the present invention. -
FIG. 3 is a description of attributes of the formulation of the present invention. -
FIGS. 4-6 are descriptions of the attributes of the formulation of the present invention used to treat specified skin conditions. -
FIG. 7 is a perspective view of devices for application of the formulation of the present invention. - One embodiment of the present invention includes a method for making an array of formulations tailored for treating specific types of mucosal discontinuities. The method includes providing phenol, guaiacol, sulfuric acid and, optionally, water in preselected concentrations; reacting the guaiacol and phenol with the sulfuric acid and water to make phenolsulfonic acid and guaiacolsulfonic acid and, for some embodiments, free water and free acid to produce a formulation having a preselected concentration of preselected isomers of phenolsulfonic acid, preselected isomers of guaiacolsulfonic acid, and optionally, free acid and free water.
- Another embodiment of the present invention includes a formulation for treating mucosal discontinuities, comprising: phenolsulfonic acid and isomers of phenolsulfonic acid; guaiacolsulfonic acid and isomers of guaiacolsulfonic acid and mono- and bis-forms of guaiacolsulfonic acid; ammonium phenolsulfonate; and potassium guaiacolsulfonate.
- Another embodiment of the present invention includes a formulation for treating oral mucosal discontinuities, comprising: phenolsulfonic acid in a concentration of 25-80% by weight; guaiacolsulfonic acid in a concentration of 25-80% by weight; free sulfuric acid in a concentration of 13 to 32% by weight; and water in a concentration of 0 to 3% by weight.
- One other embodiment includes a formulation for treating skin mucosal discontinuities, comprising: phenolsulfonic acid in a concentration of 25-80% by weight; ammonium phenolsulfonate in a concentration of 0 to 5% by weight; guaiacolsulfonic acid in a concentration of 25-80% by weight; free sulfuric acid in a concentration of 0 to 32% by weight; and water in a concentration of 0 to 3% by weight.
- Another embodiment includes a device for treating mucosal discontinuities, comprising: a syringe, and the formulation of the present invention contained in the syringe.
- One other embodiment of the present invention includes a system comprising: ingredients that include phenolsulfonic acid, guaiacolsulfonic acid, ammonium phenolsulfonate, potassium guaiacolsulfonate, water and free acid; and a mechanism calibrated to mix preselected amounts of two or more of the ingredients together to make a formulation for treating a specific type of mucosal discontinuity.
- In its method and system aspects, the present invention includes a method and system for making an array of formulations tailored for treating specific types of mucosal discontinuities. The method includes providing phenol, guaiacol, sulfuric acid and, optionally, water, and reacting the guaiacol and phenol with the sulfuric acid and, optionally, water to make phenolsulfonic acid and guaiacolsulfonic acid and, for some embodiments, free water and free acid. The preselected concentrations of guaiacol, phenol, sulfuric acid, free acid and water produce a formulation having a preselected concentration of four isomers of phenolsulfonic acid, seven isomers of guaiacolsulfonic acid, and for some embodiments, free acid and free water. The specific isomer concentrations and concentration ratios are preselected by selecting specific reaction parameters such as time, temperature, and concentration of reactants that produce the preselected isomer concentration profile.
- In another embodiment, the phenolsulfonic acid is further treated with a hydroxide such as ammonium hydroxide to make ammonium phenolsulfonate. The guaiacolsulfonic acid is treated with a hydroxide such as potassium or zinc hydroxide to make potassium guaiacolsulfonate.
- The system of the present invention includes the ingredients phenolsulfonic acid, guaiacolsulfonic acid, sulfosalicylic acid, ammonium phenolsulfonate, potassium guaiacolsulfonate, water and sulfuric acid which is National Formulary (NF). The system also includes a mechanism calibrated to mix preselected amounts of the ingredients together to make a formulation for treating a specific type of mucosal discontinuity.
- As used herein, the term “mucosal discontinuity” refers to lesions, ulceration, or inflammation on the moist linings of the buccal cavity, nasal cavity, gastrointestinal tract, respiratory tract, conjunctiva, vagina, colon, urinary bladder, and urethra (Forstner et al., 1973 J. Cell. Sci. 12:585; Peppas et al., 1985 J. Control. Release 2:257; Lehr et al., 1992 J. Control Release 18:249; Spiro, 1970 Ann. Rev. Biochem. 39:599; Lebat-Robert et al., 1979 Path. Biol. 24:241).
- In one example, a formulation for treating gingivitis, one type of mucosal discontinuity, includes sulfonic acid and little or no free acid. In another example, phenolsulfonic acids and guaiacolsulfonic acids in a formulation with free sulfuric acid are used to treat periodontal disease, another type of mucosal discontinuity. In general, a formulation that includes phenolsulfonic acid, sulfosalicylic acid, and guaiacolsulfonic acid with no free acid is usable as a facial exfoliant or as a treatment for canker sores. A formulation that includes phenolsulfonic acid, sulfosalicylic acid, phenolsulfonate, and free acid is usable as a skin exfoliant for use on feet.
- In its product aspect, the present invention includes a formulation for treating mucosal discontinuities that includes phenolsulfonic acid, sulfosalicylic acid, guaiacolsulfonic acid, and, for some embodiments, ammonium phenolsulfonate, free sulfuric acid and water. In one embodiment, the formulation includes phenolic compounds that are isolated and purified, as is shown in
FIG. 1B . - The purified phenolic compounds are shown in
FIG. 2 and include phenol, guaiacol, salicylic acid, resorcinol and hydroquinone. The purified phenolics are treated with sulfuric acid to form sulfonic acids and sulfonate salts, as is shown inFIG. 1B . The sulfonate salts are treated with one or more of zinc, potassium and sodium to form a salt. Examples of other salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts. Phenolic compounds obtained from a variety of sources are usable to make the formulation of the present invention - Formulations that include the sulfonic acids of phenol and guaiacol are used to treat mucosal discontinuities in the oral cavity such as aphthous stomatitis, canker sores, chronic periodontitis and gingivitis. Formulations that include the sulfonate salts of phenol and guaiacol are used to treat mucosal discontinuities of the skin, such as dermatologic disorders. Formulations that include the phenolsulfonate salts also have use as skin resurfacing products. A breakdown of these acid and salt products is shown in
FIG. 2 . - When phenol is treated with sulfuric acid, the reaction products include four isomers of phenolsulfonic acid. When guaiacol is treated with sulfuric acid, the reaction products include seven isomers, a mono- and a bis-form of guaiacolsulfonic acid. Other sources of phenolsulfonic acid include the four isomers. Other sources of guaicol include the seven isomers, a mono- and a bis-form of guaiacolsulfonic acid.
- The method and system of the present invention is a significant improvement over methods and systems used to make formulations prepared with Beechwood creosote because the method, system, and formulations of the present invention do not have the intense phenolic odor and taste of prior art products. Furthermore, the efficacy of the formulations of the present invention is very high because the acids and salts are separated from Beechwood creosote and from each other or are synthesized in a process that does not require Beechwood creosote and are systematically and specifically blended in amounts that are targeted to treat the oral cavity and the skin, respectively.
- One formulation embodiment, for treating mucosal discontinuities of the oral cavity is described in
FIG. 4 . The formulation composition includes phenolsulfonic acid in a concentration of 30 percent by weight; guaiacolsulfonic acid in a concentration of 32 percent by weight; free sulfuric acid in a concentration of 24 percent by weight; water in a concentration of 11.9 percent by weight; and FD&C Red No. 40 in a concentration of 0.075 percent by weight. This formulation has a density of 1.59 g/mL, a total acidity of 9.1 mM/g, and a viscosity of 1025 cPs at 25 degrees Centigrade. - The formulation is applied with an applicator. The application contact time for treatment of periodontal disease is 5 to 30 seconds per infected tooth pocket. In one embodiment, the applicator is a pre-filled syringe. In another embodiment, the applicator is a kit that includes a topical anesthetic and an application device such as the pre-filled syringe. The topical local anesthetic is applied with any conventional applicator such as a cotton swab. As used herein, the term “local anesthetic” means any drug that provides local numbness or analgesia or any drug that provides a regional blockage of nociceptive pathways (afferent and/or efferent) and that is not an agonist or an antagonist of an opioid receptors. The local anesthetic can be any local anesthetic known or to be developed. Examples of local anesthetics suitable for use with the invention include: ambucaine, amolanone, amylcaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethisoquin, dimethocaine, diperodon, dyclonine, ecogonidine, ecogonine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxyteteracaine, isobutyl p-aminobenzoate, leucinocaine, levoxadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloride, myrtecaine, naepaine, octacaine, orthocaine, oxethazaine, parenthoxycaine, phenacaine, phenol, piperocaine, piridocaine, polidocanol, pramoxine, prilocalne, procaine, propanocaine, proparacaine, propipocaine, propoxycaine, pseudococaine, pyrrocaine, ropivacaine, salicyl alcohol, tetracaine, tolycaine, trimecaine, zolamine, or pharmaceutically-acceptable salts thereof, or mixtures thereof. The anesthetic is separately packaged for some embodiments and incorporated into the formulation for other embodiments.
- Some kit and formulation embodiments include an analgesic. Examples of suitable analgesics include, but are not limited to, aceclofenac, acetaminophen, acetaminosalol, acetanilide, acetylsalicylsalicylic acid, alclofenac, alminoprofen, aloxiprin, aluminum bis(acetylsalicylate), aminochlorthenoxazin, 2-amino-4-picoline, aminopropylon, aminopyrine, ammonium salicylate, amtohnetin guacil, antipyrine, antipyrine salicylate, antrafenine, apazone, aspirin, benorylate, benoxaprofen, benzpiperylon, benzydamine, bermoprofen, bromfenac, p-bromoacetanilide, 5-bromosalicylic acid acetate, bucetin, bufexamac, bumadizon, butacetin, calcium acetylsalicylate, carbamazepine, carbiphene, carsalam, chlorthenoxazin(e), choline salicylate, cinchophen, ciramadol, clometacin, clonixin, cropropamide, crotethamide, dexoxadrol difenamizole, difiunisal, dihydroxyaluminum acetylsalicy, late, dipyrocetyl, dipyrone, emorfazone, enfenamic acid, epirizole, etersalate, ethenzamide, ethoxazene, etodolac, felbinac, fenoprofen, floctafenine, flufenamic acid, fluoresone, flupirtine, fluproquazone, flurbiprofen, fosfosal, gentisic acid, glafenine, ibufenac, imidazole salicylate, indomethacin, indoprofen, isofezolac, isoladol, isonixin, ketoprofen, ketorolac, p-lactophcnetide, lefetamine, lomoxicam, loxoprofen, lysine acerylsalicylate, magnesium acetylsalicylate, methotrimeprazine, metofoline, mofezolac, morazone, morpholine salicylate naproxen, nefopam, nifenazone, 5′-nitro-2′-propoxyacetanilide, parsalmide, perisoxal, phenacetin, phenazopyridine hydrochloride, phenocoll, phenopyrazone, phenyl acetylsalicylate, phenyl salicylate, phenyramidol, pipebuzone, piperylone, propacetamol, propyphenazone, ramifenazone, rimazolium metilsulfate, salacetamide, salicin, salicylamide, salicylamide o-acetic acid, salicylsulfuric acid, salsalate, salverine, simetride, sodium salicylate, suprofen, talniflumate, tenoxicam, terofenamate, tetrandrine, tinoridine, tolfenamic acid, tramadol, tropesin, viminol, xenbucin, and zomepirac
- Acceptable component ranges for a formulation for treating mucosal discontinuities of the oral cavity, such as gingivitis, are as follows:
Component Concentration Ranges Phenolsulfonic Acid 25-80% by weight Guaiacolsulfonic Acid 25-80% by weight Sulfosalicylic Acid 0-30% by weight Citric Acid 0-30% by weight Ammonium Phenolsulfonate 0-32% by weight Free Sulfuric Acid 0-32% by weight Water 13-30% by weight - Acceptable component ranges for a formulation for treating mucosal discontinuities of the skin are as follows:
Component Concentration Ranges Phenolsulfonic Acid 25-80% by weight Guaiacolsulfonic Acid 25-80% by weight Ammonium Phenolsulfonate 0-5% by weight Free Sulfuric Acid 0-3% by weight Water 0-30% by weight Colorant 0.075-0.020% by weight
These mucosal discontinuities include sores such as canker sores. - Another formulation embodiment of the present invention is for treatment of periodontal disease. Acceptable concentration ranges are as follows:
Component Concentration Ranges Phenolsulfonic Acid 25 to 80% Guaiacolsulfonic Acid 25 to 80 % Ammonium Phenolsulfonate 0 to 32% Free Sulfuric Acid 0 to 32 % Water 0 to 30% Colorant 0.00 to 0.075% - The viscosity is 70 to 1000 cPs. The total acidity is 7.20 to 9.20 mM/g. The density is 1.46 to 1.59 g/mL. The application time is 5 to at least 60 seconds. The applicator includes in some embodiments, a vial, a pre-filled syringe, or a swab or combinations of these applicators. The formulation optionally includes a colorant such as green or blue.
- The formulation of the present invention has use as a liquid chemical cauterization agent for, in one embodiment, the oral cavity mucosa. The mechanisms of therapeutic action include solvent and keratolytic-based mechanisms that include penetrating and dissolving necrotic tissues. The mechanism also includes hygroscopic and dehydrating-based mechanisms. In particular, the formulation reduces tissue edema. The solvation is exothermic. The solvation releases acidification. The mechanism is also a denaturant and keratocoagulant-based. The formulation causes acidification necrosis and oxidation. The formulation also aids in generation of a surrogate Eschar/clot that acts as a protective natural bandage.
- The formulation of the present invention provides instantaneous pain relief to a user and accelerates ulcer healing. The formulation kills infectious organisms and is effective in a single application applied to an ulcer or other mucosal discontinuity. The formulation of the present invention is self-limited and is not harmful to healthy mucosa. The reaction of the formulation is limited by water solvation, barrier membrane formation, and acid neutralization.
- Devices for applying the formulations of the present invention are shown in
FIG. 7 and include a syringe and a cotton swab. In one embodiment, the syringe is prefilled. In one embodiment, the formulation of the present invention is enclosed within a swab device. In another embodiment, the formulation is enclosed in a container with a delivery mechanism that delivers the formulation drop-by-drop. In another embodiment, the formulation is metered. In one other embodiment, the formulation is enclosed in a container that includes a mechanism for heating or cooling the formulation. The mechanism includes chemicals, separated in compartments by a breakable seal, adjacent to the formulation of the present invention, that create either an exothermic or endothermic reaction when combined. In one embodiment, the chemicals are separated from the formulation by a wall. The chemicals are combined when a user breaks the breakable seal. The heating or cooling is transferred to the formulation through the wall. The packaged formulation of the present invention is transported for sale to pharmacies and drug stores. In other embodiments, the formulation of the present invention is packaged with an anesthetic. The anesthetic is applied to the mucosal discontinuity first. - In its method aspect, one embodiment of the present invention includes a method for preparing treatments for mucosal discontinuities in the oral cavity and skin. One method embodiment is described in the following example:
- Phenolsulfonic acid solution was prepared in sulfuric acid. The method included setting up a recirculating water bath so that the water was at a temperature of 95 degrees Centigrade. Next, the weight of available stock of Liquified Phenol USP containing 3.23 moles of Phenol was calculated. Phenol has a molecular weight of 94.11. The weight of 3.23 moles of Phenol is 3.23×94.11+303.97 grams. The purity of Liquified Phenol USP typically ranges from 89.0% to 91.5%. Using the purity value either from the manufacturer's Certificate of Analysis or the purity value from an internal quality control analysis, the weight of the available stock of Liquified Phenol USP required to deliver 3.23 moles of Phenol was calculated.
- The amount of available stock sulfuric acid (NF) that contains 7.08 moles was calculated. The purity of sulfuric acid NF typically ranges from 95.0% to 98%. A 1 liter Corning Pyrex Bottle No. 1395 was placed on a Mettler PG-5002-S balance. A 600 mL beaker was filled with about 400 mL of Liquified Phenol USP from the stock bottle. A quantity of 3.23 moles of phenol as liquified phenol USP by weight was added from the beaker using the weight of available stock. The amount of liquid phenol was calculated to provide 3.23 moles of phenol.
- About 400 mL of stock sulfuric acid NF were added to a 600 mL Pyrex beaker. With the 1 liter Corning bottle containing the Liquified Phenol still on the Mettler balance, 7.08 moles of sulfuric acid was added to the bottle as stock sulfuric acid NF by weight from the beaker using the weight of available stock sulfuric acid NF that was calculated to provide 7.08 moles of sulfuric acid.
- A 5 cm magnetic stirring bar was placed in the bottle containing the phenol/sulfuric acid mixture. The bottle and mixture were enclosed with a standard Corning low-temperature closure, placed on the bottle. The mixture was mixed on a magnetic stir plate for thirty minutes. The bottle was placed in a pre-heated 95 degrees Centigrade recirculating water bath for 14 to 24 hours.
- The bottle was removed from the water bath after 14 to 24 hours. The bottle was allowed to cool to room temperature and an identifying sticker was applied.
- A solution of guaiacolsulfonic acid in sulfuric acid was prepared. Water in the recirculating water bath was heated to 65 degrees Centigrade. The weight of available stock guaiacol, purified reagent, that contained 1.63 moles of guaiacol was calculated. The amount of available stock of sulfuric acid NF that contained 3.41 moles of sulfuric acid was calculated. A 1 liter Corning Pyrix bottle No. 1395 was placed on the Mettler PG-5002-S balance. A 600 mL beaker was filled with approximately 400 mL guaiacol, purified reagent from the available stock bottle. A quantity of 1.63 moles of guaiacol as guaiacol, purified reagent by weight from the beaker was added to the bottle.
- A 5 cm magnetic stir bar was placed in the bottom of the Pyrex bottle. The bottle was placed on a magnetic stir plate and stirred at low speed. A ring stand was placed next to the stir plate. A thermometer was mounted onto the ring stand so that the tip of the thermometer was positioned in the guaiacol. A 250 mL cylinder was also mounted onto the ring stand so that the tip was inserted into the opening of the Pyrex bottle.
- A 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF. A second 600 mL beaker was placed on the Mettler PG-5002-S balance. A quantity of 3.41 moles of sulfuric acid as stock sulfuric acid NF was added to the second beaker. With the cylinder stopcock in the closed position, the weighed amount of sulfuric acid NF was transferred from the second beaker to the addition cylinder mounted above the Pyrex bottle containing the measured quantity of guaiacol. The sulfuric acid was added from the addition cylinder to the guaiacol in the bottle in 10 to 20 mL aliquots while maintaining steady stirring. The temperature of the mixture was monitored to maintain a range of 55 to 65 degrees Centigrade until all of the acid was placed in the bottle.
- The reaction mixture was stirred for 30 minutes after all of the sulfuric acid was added to the mixture. The mixture was enclosed by a standard Corning low temperature closure on the bottle. The bottle was placed in a pre-heated 65 degrees Centigrade recirculating water bath for 14 to 24 hours. The bottle was removed after the 14 to 24 hours and allowed to come to room temperature. The bottle was then marked.
- The phenolsulfonic acid solution and the guaiacolsulfonic acid solution were then subjected to quality control. After being release by Quality Control, 1000 grams of the phenolsulfonic acid solution and 500 grams of the guaiacolsulfonic acid solution were prepared in a 2 liter Corning Pyrix bottle No. 1395 using the Mettler PG-5002-S balance. A quantity of 1.125 grams of FD&C Red #40 powdered colorant was weighed and added to the phenolsulfonic/guaiacolsulfonic mixture. The bottle was mixed by inverting repeatedly until the color was evenly dispersed. The colored phenolsulfonic/guaiacolsulfonic mixture was then available for use.
- A facial exfoliant was prepared. A solution of phenolsulfonic acid was prepared as described in Example 1, except that the weight of available stock liquefied phenol USP was calculated and prepared for 4.0 moles of phenol. The amount of available stock sulfuric acid NF that contained 4.0 moles was calculated. The weight of sulfuric acid NF was 392.32 grams. The 4.0 moles of sulfuric acid NF was treated as described in Example 1. A quantity of 400 mL of Liquified Phenol USP was added to a 600 mL beaker. A quantity of 4.0 moles of phenol as Liquefied Phenol USP was added to a 1 L Corning Pyrex No. 1395 bottle using the Mettler PS-5002-S balance.
- A second 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF. With the 1 L Corning bottle containing the liquefied phenol still on the Mettler balance, 4.0 moles of sulfuric acid as stock sulfuric acid NF by weight, was added to the bottle.
- A 5 cm magnetic stirring bar was placed in a bottle containing the phenol/sulfuric acid mixture and enclosed with a Corning low-temperature closure. The solution was mixed for 30 minutes. The bottle was then placed in a pre-heated 95 degree Centigrade recirculating water bath for 14 to 24 hours. After 14 to 24 hours, the bottle was removed and allowed to come to room temperature and marked with a sticker.
- The weight of available stock guaiacol, purified reagent that contained 3.50 moles of guaiacol was calculated. The amount of available stock sulfuric acid NF that contained 3.50 moles of sulfuric acid was also calculated. A 1 L Corning Pyrex bottle No. 1395 was placed on the Mettler PG-5002-S balance. A 600 mL beaker was filled with approximately 400 mL of guaiacol, purified reagent. A quantity of 3.50 moles of guaiacol was added from the beaker to the 1 L Pyrex bottle. A quantity of 3.50 moles of sulfuric acid NF was added to the 1 L Pyrex bottle, as described in Example 1, in 10 to 20 mL aliquots while maintaining steady stirring between 55 to 65 degrees Centigrade until all of the acid had been placed in the bottle. The mixture was continuously stirred for 30 minutes after all of the sulfuric acid has been added and a Corning low temperature closure was placed on the bottle. The bottle was placed in a pre-heated 65 degree Centigrade recirculating water bath for 14 to 24 hours. The bottle was removed from the water bath after 14 to 24 hours. The bottle was allowed to come to room temperature and was then marked for quality control.
- A quantity of 750 grams of the phenolsulfonic acid solution and 750 grams of the guaiacolsulfonic acid solution were combined in a 2 L Corning Pyrex bottle. A quantity of 1.5 grams of Citronellal fragrance was added. The acids were mixed by inverting the bottle repeatedly until evenly blended.
- The method also includes treating the purified phenolics with sulfuric acid to make sulfonic acids and sulfonate salts. The method further includes using the sulfonic acids to treat mucosal discontinuities in the oral cavity such as aphthous stomatitis, chronic periodontitis, canker sores, and gingivitis. The method includes using the sulfonate salts to treat dermatologic disorders and for skin resurfacing.
- A skin exfoliant for use on feet was prepared. A solution of phenolsulfonic acid was prepared as described in Example 1, except that the weight of available stock liquefied phenol USP was calculated and prepared for 5.0 moles of phenol. The amount of available stock sulfuric acid NF that contained 5.0 moles was calculated. The weight of sulfuric acid NF was 490.4 grams. The 5.0 moles of sulfuric acid NF was treated as described in Example 1. A quantity of 470.55 gms of Liquified Phenol USP was added to a 600 mL beaker. A quantity of 5.0 moles of phenol as Liquefied Phenol USP was added to a 1 L Corning Pyrex No. 1395 bottle using the Mettler PS-5002-S balance.
- A second 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF. With the 1 L Corning bottle containing the liquefied phenol still on the Mettler balance, 5.0 moles of sulfuric acid as stock sulfuric acid NF by weight, was added to the bottle.
- A 5 cm magnetic stirring bar was placed in a bottle containing the phenol/sulfuric acid mixture and was enclosed with a Corning low-temperature closure. The solution was mixed for 30 minutes. The bottle was then placed in a pre-heated 95 degree Centigrade recirculating water bath for 14 to 24 hours. After 14 to 24 hours, the bottle was removed and was allowed to come to room temperature and marked with a sticker.
- The phenolsulfonic acid and beaker were placed on the Mettler balance. A quantity of 300 grams of reagent grade ammonium phenolsulfonate was added to the phenolsulfonic acid. A quantity of 30 grams of reagent grade zinc phenolsulfonate was added to the phenolsulfonic acid. A quantity of 1.5 grams of Citronellal fragrance was added. The acids were mixed by vigorous stirring using a power hand blender.
- A treatment for canker sores was formulated. A solution of phenolsulfonic acid was prepared as described in Example 1, except that the weight of available stock liquefied phenol USP was calculated and prepared for 2.4 moles of phenol. The amount of available stock sulfuric acid NF that contained 5.26 moles was calculated. The weight of sulfuric acid NF was 515.90 grams. The 5.26 moles of sulfuric acid NF was treated as described in Example 1. A quantity of 400 mL of Liquified Phenol USP was added to a 600 mL beaker. A quantity of 2.4 moles of phenol as Liquefied Phenol USP was added to a 1 L Corning Pyrex No. 1395 bottle using the Mettler PS-5002-S balance.
- A second 600 mL Pyrex beaker was filled with approximately 400 mL of stock sulfuric acid NF. With the 1 L Corning bottle containing the liquefied phenol still on the Mettler balance, 5.26 moles of sulfuric acid as stock sulfuric acid NF by weight, was added to the bottle.
- A 5 cm magnetic stirring bar was placed in a bottle containing the phenol/sulfuric acid mixture and enclosed with a Corning low-temperature closure. The solution was mixed for 30 minutes. The bottle was then placed in a pre-heated 95 degree Centigrade recirculating water bath for 14 to 24 hours. After 14 to 24 hours, the bottle was removed and allowed to come to room temperature and marked with a sticker.
- The weight of available stock guaiacol, purified reagent that contains 2.3 moles of guaiacol was calculated. The amount of available stock sulfuric acid NF that contains 4.82 moles of sulfuric acid was also calculated. A 1 L Corning Pyrex bottle No. 1395 was placed on the Mettler PG-5002-S balance. A 600 mL beaker was filled with approximately 400 mL of guaiacol, purified reagent. A quantity of 2.3 moles of guaiacol was added from the beaker to the 1 L Pyrex bottle. A quantity of 4.82 moles of sulfuric acid NF was added to the 1 L Pyrex bottle, as described in Example 1, in 10 to 20 mL aliquots while maintaining steady stirring between 55 to 65 degrees Centigrade until all of the acid had been placed in the bottle. Stirring was continued for 30 minutes after all of the sulfuric acid has been added and a Corning low temperature closure was placed on the bottle. The bottle was placed in a pre-heated 65 degree Centigrade recirculating water bath for 14 to 24 hours. The bottle was removed from the water bath after 14 to 24 hours. The bottle was allowed to come to room temperature and then was marked for quality control.
- A quantity of 750 grams of the phenolsulfonic acid solution and 750 grams of the guaiacolsulfonic acid solution were combined in a 2 L Corning Pyrex bottle. A quantity of 1.5 grams of Citronellal fragrance was added. The acids were mixed by inverting the bottle repeatedly until evenly blended.
- The method also includes treating the purified phenolics with sulfuric acid to make sulfonic acids and sulfonate salts. The method further includes using the sulfonic acids to treat mucosal discontinuities in the oral cavity such as aphthous stomatitis, chronic periodontitis and gingivitis. The method includes using the sulfonate salts to treat dermatologic disorders and for skin resurfacing.
- Since the invention disclosed herein may be embodied in other specific forms without departing from the spirit or general characteristics thereof, some of which forms have been indicated, the embodiments described herein are to be considered in all respects illustrative and not restrictive. The scope of the invention is to be indicated by the appended claims, rather than by the foregoing description, and all changes, which come within the meaning and range of equivalency of the claims, are intended to be embraced therein.
Claims (16)
1-9. (canceled)
10. A method for exfoliating skin, comprising:
packaging an exfoliating composition comprising phenolsulfonic acid, guaiacolsulfonic acid and, optionally, sulfosalicylic acid.
11-15. (canceled)
16. The method of claim 10 , further comprising providing instructions for using the exfoliating composition to exfoliate skin.
17. The method of claim 10 , further comprising packaging the exfoliating composition in a container capable of dispensing a predetermined quantity of exfoliating composition that is effective for exfoliating skin.
18. The method of claim 10 , further comprising packaging the exfoliating composition in predetermined quantities of exfoliating composition effective for exfoliating skin.
19. The method of claim 10 , further comprising packaging the exfoliating composition with an applicator.
20. The method of claim 10 , further comprising packaging the exfoliating composition with a mechanism capable of heating or cooling the exfoliating composition.
21. The method of claim 19 , wherein the applicator includes one or more of an abrasive pad, a brush, an abrasive board, or other abrasive device.
22. The method of claim 10 , further comprising further comprising providing instructions for using the exfoliating composition to exfoliate skin.
23. The method of claim 10 , wherein the exfoliating composition is a cream or paste.
24. The method of claim 10 , wherein the exfoliating composition is a gel.
25. The method of claim 10 , further comprising packaging the exfoliating composition with instructions for exfoliating callouses.
26. The method of claim 10 , wherein the exfoliating composition further comprises an emulsifier.
27. The method of claim 10 , wherein the exfoliating composition further comprises a preservative.
28. The method of claim 10 , wherein the exfoliating composition further comprises an emollient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/533,194 US20070025927A1 (en) | 2003-01-03 | 2006-09-19 | Odorless formulation for treating mucosal discontinuities |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43777703P | 2003-01-03 | 2003-01-03 | |
US10/443,446 US7132111B2 (en) | 2003-01-03 | 2003-05-21 | Odorless formulation for treating mucosal discontinuities |
US11/533,194 US20070025927A1 (en) | 2003-01-03 | 2006-09-19 | Odorless formulation for treating mucosal discontinuities |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/443,446 Continuation US7132111B2 (en) | 2003-01-03 | 2003-05-21 | Odorless formulation for treating mucosal discontinuities |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070025927A1 true US20070025927A1 (en) | 2007-02-01 |
Family
ID=36788719
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/443,446 Active 2024-09-16 US7132111B2 (en) | 2003-01-03 | 2003-05-21 | Odorless formulation for treating mucosal discontinuities |
US11/533,194 Abandoned US20070025927A1 (en) | 2003-01-03 | 2006-09-19 | Odorless formulation for treating mucosal discontinuities |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/443,446 Active 2024-09-16 US7132111B2 (en) | 2003-01-03 | 2003-05-21 | Odorless formulation for treating mucosal discontinuities |
Country Status (2)
Country | Link |
---|---|
US (2) | US7132111B2 (en) |
CN (1) | CN1791381A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170281572A1 (en) * | 2014-09-02 | 2017-10-05 | Epien Medical, Inc. | Formulation for treating chronic wounds |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115251B2 (en) * | 2003-05-21 | 2006-10-03 | Northern Research Laboratories, Inc. | Method for exfoliating skin |
US7132111B2 (en) * | 2003-01-03 | 2006-11-07 | Epien Medical, Inc. | Odorless formulation for treating mucosal discontinuities |
US20060100274A1 (en) * | 2004-11-05 | 2006-05-11 | Trustees Of Tufts College | Therapeutic avenanthramide compounds |
US20070254055A1 (en) * | 2003-11-21 | 2007-11-01 | Trustees Of Tufts College | Therapeutic Avenanthramide Compounds |
US20050239892A1 (en) * | 2003-11-21 | 2005-10-27 | Trustees Of Tufts College | Therapeutic avenathramide compounds |
US20070005026A1 (en) * | 2005-06-21 | 2007-01-04 | Michael Basara | Method and material for reducing biofilm |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459800A (en) * | 1964-03-01 | 1969-08-05 | Salat Carlos F | Phenolsulfonic acid derivatives of tetracycline antibiotics |
US3920836A (en) * | 1972-09-27 | 1975-11-18 | Askew Anthony B | Sanitizing plastic material |
US3988470A (en) * | 1974-02-25 | 1976-10-26 | Scott Eugene J Van | Treatment of palmar and plant disturbed keratosis |
US4060212A (en) * | 1976-04-01 | 1977-11-29 | System Development Corporation | Deicing apparatus and method |
US4144325A (en) * | 1976-11-10 | 1979-03-13 | Voyt Walter F | Method of and composition for preventing sunburn while affording tanning |
US4331653A (en) * | 1977-08-18 | 1982-05-25 | Robert Brown | Composition for a topical cream for curtailing bleeding and treating skin disorders |
US4416982A (en) * | 1980-11-14 | 1983-11-22 | Kyowa Hakko Kogyo Co., Ltd. | Composition and method for decomposing hydrogen peroxide |
US4968539A (en) * | 1987-12-01 | 1990-11-06 | Lion Corporation | Liquid crystal membrane |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
US5688995A (en) * | 1995-05-18 | 1997-11-18 | Ciba-Geigy Corporation | o-Hydroxyphenyl-s-triazines |
US20020168334A1 (en) * | 2001-02-15 | 2002-11-14 | Jacob Jeremy E. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
US6596299B1 (en) * | 2000-05-19 | 2003-07-22 | Northern Research Laboratories, Inc. | Method of treating periodontal disease |
US20040234490A1 (en) * | 2003-05-21 | 2004-11-25 | Michael Basara | Method for exfoliating skin |
US6846846B2 (en) * | 2001-10-23 | 2005-01-25 | The Trustees Of Columbia University In The City Of New York | Gentle-acting skin disinfectants |
US7132111B2 (en) * | 2003-01-03 | 2006-11-07 | Epien Medical, Inc. | Odorless formulation for treating mucosal discontinuities |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB820659A (en) | 1957-02-26 | 1959-09-23 | Hardman & Holden Ltd | Improvements relating to the sulphonation of phenols |
US3984556A (en) * | 1973-01-19 | 1976-10-05 | Sandoz, Inc. | Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure |
US3879537A (en) * | 1973-09-04 | 1975-04-22 | Scott Eugene J Van | Treatment of ichthyosiform dermatoses |
JPS6050763B2 (en) * | 1975-06-30 | 1985-11-11 | 忠一 高橋 | Manufacturing method for vital dental pulp covering and root canal filling material |
US4082841A (en) * | 1975-10-10 | 1978-04-04 | Lever Brothers Company | Dentifrice |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
CA2512345A1 (en) | 2003-01-03 | 2004-07-29 | Epien Medical, Inc. | Odorless formulation for treating mucosal discontinuities |
-
2003
- 2003-05-21 US US10/443,446 patent/US7132111B2/en active Active
-
2004
- 2004-01-05 CN CN200480003865.8A patent/CN1791381A/en active Pending
-
2006
- 2006-09-19 US US11/533,194 patent/US20070025927A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459800A (en) * | 1964-03-01 | 1969-08-05 | Salat Carlos F | Phenolsulfonic acid derivatives of tetracycline antibiotics |
US3920836A (en) * | 1972-09-27 | 1975-11-18 | Askew Anthony B | Sanitizing plastic material |
US3988470A (en) * | 1974-02-25 | 1976-10-26 | Scott Eugene J Van | Treatment of palmar and plant disturbed keratosis |
US4060212A (en) * | 1976-04-01 | 1977-11-29 | System Development Corporation | Deicing apparatus and method |
US4144325A (en) * | 1976-11-10 | 1979-03-13 | Voyt Walter F | Method of and composition for preventing sunburn while affording tanning |
US4331653A (en) * | 1977-08-18 | 1982-05-25 | Robert Brown | Composition for a topical cream for curtailing bleeding and treating skin disorders |
US4416982A (en) * | 1980-11-14 | 1983-11-22 | Kyowa Hakko Kogyo Co., Ltd. | Composition and method for decomposing hydrogen peroxide |
US4968539A (en) * | 1987-12-01 | 1990-11-06 | Lion Corporation | Liquid crystal membrane |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
US5688995A (en) * | 1995-05-18 | 1997-11-18 | Ciba-Geigy Corporation | o-Hydroxyphenyl-s-triazines |
US6596299B1 (en) * | 2000-05-19 | 2003-07-22 | Northern Research Laboratories, Inc. | Method of treating periodontal disease |
US20030185768A1 (en) * | 2000-05-19 | 2003-10-02 | Northern Research Laboratories, Inc. | Method of treating periodontal disease |
US6830757B2 (en) * | 2000-05-19 | 2004-12-14 | Northern Research Laboratories, Inc. | Method of treating periodontal disease |
US20020168334A1 (en) * | 2001-02-15 | 2002-11-14 | Jacob Jeremy E. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
US6846846B2 (en) * | 2001-10-23 | 2005-01-25 | The Trustees Of Columbia University In The City Of New York | Gentle-acting skin disinfectants |
US7132111B2 (en) * | 2003-01-03 | 2006-11-07 | Epien Medical, Inc. | Odorless formulation for treating mucosal discontinuities |
US20040234490A1 (en) * | 2003-05-21 | 2004-11-25 | Michael Basara | Method for exfoliating skin |
US7115251B2 (en) * | 2003-05-21 | 2006-10-03 | Northern Research Laboratories, Inc. | Method for exfoliating skin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170281572A1 (en) * | 2014-09-02 | 2017-10-05 | Epien Medical, Inc. | Formulation for treating chronic wounds |
US10849868B2 (en) * | 2014-09-02 | 2020-12-01 | Epien Medical, Inc. | Formulation for treating chronic wounds |
Also Published As
Publication number | Publication date |
---|---|
US20040132810A1 (en) | 2004-07-08 |
US7132111B2 (en) | 2006-11-07 |
CN1791381A (en) | 2006-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070025927A1 (en) | Odorless formulation for treating mucosal discontinuities | |
CA2412708C (en) | Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions | |
US4610978A (en) | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same | |
US5958984A (en) | Method and composition for skin treatment | |
US8536228B2 (en) | Transdermal compositions | |
US5874479A (en) | Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same | |
ES2236352T3 (en) | ANTIMICROBIAL LOTION OF RAPID ACTION OF INCREASED EFFECTIVENESS. | |
US20050220742A1 (en) | Compositions and methods for maintaining eyelid hygiene | |
ES2208834T3 (en) | DUAL PHASE COSMETIC COMPOSITION. | |
US20020164381A1 (en) | Mitocidal compositions and methods | |
BRPI0611713A2 (en) | topical skin care compositions | |
USRE33107E (en) | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same | |
US9629872B2 (en) | Sodium thiosulphate for the treatment of ectopic calcifications | |
EP1570850A1 (en) | Topical formulations for treatment of rosacea | |
EP1050300A2 (en) | Selective antibacterial composition | |
PT94687A (en) | A process for the preparation of a creamy and stable creamy composition containing transethicin (RETINOIC ACID, ALL TRANS AND VITAMIN A ACID) | |
EP1587477B1 (en) | Odorless formulation for treating mucosal discontinuities | |
US20080287373A1 (en) | Topical skin treating kits | |
US5128375A (en) | Keloid treating agent | |
US7939568B2 (en) | Use of a composition comprising vitamin K1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions | |
JP2000212090A (en) | Skin-modifying agent | |
JPH07267869A (en) | Remedy and method for medical treatment for dermatosis | |
WO2004093996A1 (en) | Topical sulfacetamide composition and method for treating seborrheic dermatitis | |
JPS6056921A (en) | Dermatic drug for external application | |
JPS6028924A (en) | External preparation for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |